The Role of Angiotensin II on Human and Partial Bladder Outlet Obstructed Rabbit Corpus Cavernosal Contractility: Modulation of Nitric Oxide-Mediated Relaxation and Relevance to Erectile Dysfunction by Ertemi, HS
 
 
 1 
___________________________________ 
The role of angiotensin II on human and partial 
bladder outlet obstructed rabbit corpus 
cavernosal contractility: modulation of nitric 
oxide-mediated relaxation and relevance to 
erectile dysfunction 
________________________________________ 
A thesis presented for the degree of Doctor of Medicine in Urology to the 
Faculty of Biomedical Sciences, Division of Surgery and Interventional Science, 
University College London 
Submitted 2013  
By 
HANI SEDIGH ERTEMI  
MBBCh, MRCS (England) 
Departments of Surgery and Clinical Biochemistry 
University College London Medical School, Royal Free Campus, Pond Street, 
Hampstead 
London. NW3 2QG 
 
 
 2 
ABSTRACT  
 
The interaction between angiotensin II (Ang II), a smooth muscle constrictor peptide 
and nitric oxide (NO) a vasodilator, as well as the role of oxidative stress (OS), have 
been investigated in human and chronic partial bladder outlet obstructed (PBOO) 
rabbit corpus cavernosal tissue. The PBOO rabbit model is characterised by an 
increase in corpus cavernosal collagen deposition and a marked reduction and 
impaired relaxation of corpus cavernosal smooth muscle (CCSM) cells, making it a 
useful model for erectile dysfunction (ED).  
Immunohistochemical analysis identified Ang II peptide distribution in human corpus 
cavernosal tissue, while organ bath studies determined the Ang II/NO interaction. OS 
was determined using apocynin and diphenylene iodonium chloride (DPI), inhibitors 
of NAD(P)H oxidase, which inhibit superoxide production and superoxide dismutase 
(SOD, the enzyme that accelerates the breakdown of superoxide).  
Human penile Ang II was distributed in the arteriolar endothelium, the endothelium 
lining sinusoids and CCSM cells. The peptide caused a dose dependent contraction 
of CCSM strips that was inhibited by losartan (AT1 receptor antagonist) and 
apocynin. In contrast, CCSM relaxation induced by either sodium nitroprusside 
(SNP, an NO donor) or electrical field stimulation (EFS) was potentiated by losartan.  
The Ang II contractile response was enhanced in CCSM strips taken from PBOO 
rabbits and inhibited by losartan, DPI and SOD. CCSM relaxation induced by 
SNP/EFS was impaired in this model and improved by vardenafil (PDE5 inhibitor) 
and losartan.   
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Taken together, these findings suggest that Ang II and NO interact to modulate 
human and rabbit penile smooth muscle tone. Moreover, the Ang II response 
involves the production of superoxide and the development of OS. The increase in 
Ang II-mediated CCSM contraction following PBOO is likely to be a pathological 
consequence of the condition. Importantly, AT1 receptor inhibition may be a 
therapeutic target for the treatment of ED associated with PBOO. 
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Chapter one 
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General Introduction 
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1.1 Anatomy of the penis 
The human penis is a pendulous organ suspended from the anterior and lateral 
aspect of the pubic arch containing the distal part of the urethra. It is composed of 
three erectile bodies running in parallel; the corpus spongiosum, encompassing the 
urethra and terminating in the glans penis; and the two corpus cavernosa (CC) which 
function as blood filled capacitors providing the structure to the erect organ 
(Andersson and Wagner, 1995). The penile CC is a highly specialized vascular 
structure that is morphologically adapted to their function of becoming engorged 
during sexual arousal. The trabecular smooth muscle constitutes approximately 40-
50% of tissue cross sectional area, as assessed by histomorphometreic analysis 
(Nehra et al, 1998). The cavernosal tissue is composed of a complex meshwork of 
interconnected cavernosal spaces, or sinusoids, lined by vascular endothelium. Each 
sinusoid is separated by trabeculae consisting of fibrous tissue, elastic fibres and 
plain muscular fibre this fibro-elastic network, which fills with blood during erection. 
The relationship/architecture of these structures can be seen in the scanning 
electron micrographs of a normal rabbit corpus cavernosum shown in Fig 1. 
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Figure 1. Scanning electron micrograph from a representative cavernosa of a 6 
month control rabbit (scale bar 50µm). Adapted with permission from Dr C S 
Thompson.  
1.1.1 Blood supply of the penis  
There are three main arteries of the penis; cavernosal, dorsal and bulbourethral. All 
three arise from a shared branch of the internal pudendal artery and provide an 
extensive vascular network (Yiee, 2010). 
Nowadays, there is a tendency to perform in vitro experiments using the pudendal 
artery to investigate pathophysiological aspects of penile function, since the artery is 
the major resistance to penile engorgement during sexual stimulation.     
The CC arterial blood supply is mainly fed from the deep penile cavernosal artery 
(Andersson and Wagner, 1995), which cause corporal enlargement during erection, 
whereas the deep dorsal artery is more likely to cause glans enlargement. 
The architecture of venous drainage is completely different to that of the arterial 
supply; there exists only one deep dorsal vein that runs alongside the dorsal arteries 
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(Fig 2) and nerves in Buck’s fascia above the tunica albuginea, which is a 
multilayered structure where emissary veins pass (Moscovici et al, 1999). 
.  
1.1.2 Nervous supply of the Penis  
The innervation of the penis is both autonomic (sympathetic and parasympathetic) 
and somatic (sensory and motor). From the neurons in the spinal cord and peripheral 
ganglia, the sympathetic and parasympathetic nerves merge to form the cavernous 
nerves, which enter in the CC and corpus spongiosum to affect neurovascular 
events during the tumescence and detumescence (Dean and Lue, 2005). 
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Removed for copy right reason 
 
Figure 2. Penile anatomy. Adapted from Fazio and Brock (Erectile           
dysfunction:management update) , 2004 
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1.2 Physiology of penile erection 
Penile erection is elicited by a physiologically unique sequence of events (Goldstein 
& Udelson, 1998; Andersson, 2001; Carson & Lue, 2005; Giulano & Rampin, 2004; 
Argiolas & Melis, 2005). On male sexual arousal higher cerebral centres in the 
paraventricular nucleus of the hypothalamus and limbic system are activated 
(Anderson & Wagner, 1995). Central neurotransmitters implicated in the control of 
erection include dopamine, serotonin, noradrenalin, opiates, oxytocin, prolactin and 
gamma-aminobutyric acid. The precise role of these central pathways in erectile 
physiology has been difficult to verify as the central nervous system (CNS) also 
controls other components of sexual activity, including arousal and copulation. 
However, evidence from animal experiments and studies in patients with spinal cord 
injuries has established, at least in part, that sacral spinal reflux pathways control 
erection (Giulano & Rampin, 2004; Argiolas & Melis, 2005). This spinal mechanism 
involves afferent pudendal nerve pathways communicating via interneurons to pre-
ganglionic parasympathetic neurons in the dorsal horn of the sacral spinal cord (S2-
S4) (Giulano &Rampin, 2004; Argiolas & Melis, 2005). These afferent 
parasympathetic (cholinergic) fibres reach the penis via the pelvic plexus and are 
implicated in both detumescence and ejaculation (Giulano & Rampin, 2004; Argiolas 
& Melis, 2005). 
The erectile process also involves non-adrenergic non-cholinergic (NANC) 
neurotransmission, which causes smooth muscle relaxation of the penile arteries 
and corpus cavernosum. The principal neurotransmitter during this event is nitric 
oxide (NO). This has lead to the now widely held belief that this molecule is a highly 
important component of penile erection (Trigo-Rocha et al, 1993; Burnett 1997). 
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The unique haemodynamics of erection has previously been investigated (Shirai & 
Ishii, 1981; Fournier et al, 1987, Aboseif & Lue, 1988; Goldstien & Udelson, 1998). 
These studies demonstrated that during this process the compliance of the corpora 
increases and arterial resistance decreases, exposing sinusoids to systemic blood 
pressure leading to engorgement of blood in the CC. As the flow increase and 
sinusoidal smooth muscle relax, subtunical venules draining the corpus cavernosal 
tissue become compressed against the inelastic tunica albuginae, resulting in veno-
occlusion and a rise in the intracavernosal pressure (ICP). This veno-occlusive 
mechanism is absent in the corpus spongiosum, which maintains pressure mainly 
through flow state in the glans penis. Relaxation of corpus cavernosal smooth 
muscle allows expansion of the corpora body with blood under pressure, allowing the 
penis to act as a capacitor. In the presence of adequate inflow and high outflow 
resistance, the capacitor function is limited solely by the stiffness of fibro-elastic 
elements of the penis. Detumescence occurs as a consequence of increased 
cavernosal smooth muscle tone, contraction of the sinusoids and a reduction in 
arterial inflow and venous resistance.  
 
1.2.1 The central role of nitric oxide (NO)  
Penile erection is a haemodynamic process involving increased arterial inflow and 
restricted venous outflow, co-ordinated with corpus cavernosum smooth muscle 
(CCSM) relaxation. Although this process is generally accepted to be under 
neuroregulatory control, biochemical mediators released locally from the cavernosal 
endothelium and/or smooth muscle also participates in initiating and maintaining an 
erection (Sullivan et al, 1999). Although several vasodilators have been implicated in 
erectile physiology, it is now well established that NO is the main vasodilator 
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involved (Leite et al, 2007; Toda et al, 2005). It is released by the endothelium of the 
arteries that supply the penis and the corpus cavernosum, as well as during NANC 
neurotransmission. In this capacity NO is derived from nitregic nerves (Ignarro et al, 
1990; Rajfer et al , 1992; Toda et al, 2005).  NO mediates CCSM relaxation following 
diffusion in to vascular smooth muscle cells (VSMCs), where it initiates a series of 
reactions (Fig 3). It activates soluble guanylyl cyclase (GC) to generate cyclic 
guanosine monophosphate (cGMP) (Kim et al, 1991) which activates protein kinase 
G (PKG) isoforms (Hofmann, 2005). PKG acts by phosphorylating proteins that 
modulate cellular function. Principally, the inhibition of calcium mobilization from 
intracellular stores (the sarcoplasmic reticulum), elicits CCSM and vascular smooth 
muscle relaxation, resulting in penile erection (Kim et al 1991; De Tejada 1992; 
Trigo-Rocha et al 1993; Hofmann, 2005). 
Apart from smooth muscle relaxation the NO-cGMP-PKG system also controls other 
physiological functions that protect against vascular diseases. These include 
inhibition of adhesions molecule expression, lipid oxidation, matrix protein synthesis 
and deposition, VSMC proliferation and inhibition of oxidative stress (OS) ( Muzaffar 
et al, 2005). 
The importance of the NO-cGMP-PKG axis in mediating erection is illustrated by the 
therapeutic action of phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, 
vardenafil, tadalafil), which are commonly used to treat patients with erectile 
dysfunction (ED). These drugs act by inhibiting PDE5, the enzyme that breaks down 
cyclic GMP to inactive GMP. Importantly, this process augments cGMP levels and 
leads to CCSM relaxation (Sullivan et al, 1999).  
NO is formed from the precursor amino acid L-arginine by enzymatic action of NO 
synthase (NOS), which exists in three main isoforms: neuronal NOS (nNOS), 
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inducible (iNOS) and endothelial NOS (eNOS). All three isoforms have been 
detected in penile tissue, although nNOS and eNOS are the main constitutively 
active NOS enzymes expressed (Burnett et al, 1993).  
Blood flow is another variable that should be considered in CCSM relaxation, since it 
induces fluid shear stress in the penile vasculature stimulating phosphatidyl-inositol 
3- kinase (PI3K), which phosphorylates protein kinase B (PKB), which in turn 
phosphorylates eNOS to also generate NO (Burnett, 2004). Given the dramatic 
alteration in penile flow during erection, this may represent a key mechanism that 
links nNOS to eNOS. It maybe that nNOS provides the initial dilatory trigger and NO 
derived from eNOS maintains the erection during sexual intercourse (Burnett, 2004; 
Hurt et al, 2006; Musicki &Burnett, 2006). 
This may not be the full story pertaining to NOS activity; other contributing factors 
probably play a role adding to the complexity of the process. This is illustrated by the 
fact that nNOS and eNOS deficient mice are still able to maintain erectile function 
and reproductive capacity, (Burnett, 2004; Musicki & Burnett 2006). In addition, 
sildenafil failed to augment erections in nNOS deficient mice but was effective in 
eNOS deficient mice (Cashen et al, 2002).   
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Figure 3. Physiology of erection, adapted from Mechanisms in Erectile Function and 
Dysfunction: An Overview, K P Nunes et al,2012. 
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1.3 Corpus cavernosal constrictor mediators  
The erectile response is terminated when cGMP-specific phosphodiesterase 
catalyses the hydrolysis of cGMP to 5’- GMP, thus halting the cascade of reactions 
and leading to smooth muscle contraction and concomitant detumescence (Firoozi et 
al, 2005). There is also the concomitant activation of pro-contractile 
mechanisms/mediators, which keep the smooth muscle of the penile arteries and 
trabeculae contracted (Holmquist, et al 1992). Several constrictor mediators have 
been identified and are thought to play a role in terminating penile erection. 
 
1.3.1 Noradrenaline (NA) 
Sympathetic noradrenergic fibres and parasympathetic cholinergic terminals 
innervate cavernosal tissue (Giuliano and Rampin, 2004). The sympathetic pathway 
causes detumescence via NA neurotransmission, which causes corpus cavernosal 
contraction.  
 
1.3.2 Serotonin (5-hydroxytryptamine, 5-HT) 
5-HT, a monoamine transmitter has been found in the central and peripheral nervous 
system, as well as in a number of non-neuronal cells in the gut, cardiovascular 
system and blood. 5-HT is one of the oldest neurotransmitters in evolution and has 
been implicated in the aetiology of numerous disease states, including depression, 
anxiety, hypertension and irritable bowel syndrome.  
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It is well established that neuronally-released 5-HT participates in the control of 
sexual behaviour, both in humans and animals, whereby it acts as a major modulator 
of the central neuroregulatory control of erection (Carson III, 2007). Its actions on 
erectile function are via supraspinal and spinal neurotransmission and affects both 
sympathetic, parasympathetic, and somatic outflow mechanisms (Carson, III, 2007).  
Generally, 5-HT exerts an inhibitory effect on male sexual behaviour (Bitran and Hull, 
1987). However, it also has a facilitatory role depending upon its action on other 5-
HT receptor subtypes located in the CNS (de Groat, 1993).  
Neurogenic derived 5-HT has been reported to cause human CCSM contraction via 
5-HT(1A), (1B), (2A) & (4) receptor subtypes (Lau et al, 2006). It also has a direct 
action on CCSM tissue, since it causes a profound contraction of human and rabbit 
CCSM tissue via 5-HT 2A receptor activation (Lau et al, 2006, 2007) 
It is likely that the physiological role for 5-HT is to modulate penile flaccidity, 
especially as its levels are significant elevated in cavernous serum  from normal men 
during the flaccidity/detumescence phase (Uckert et al, 2003).  
 
1.3.3 Neuropeptide Y (NPY) 
NPY has been identified in the human penis (Hauser-Kronberger et al, 1994), where 
it is co-localised with NA in sympathetic perivascular nerves and contribute to the 
vasoconstriction elicited by activation of sympathetic nerves (Ekblad et al, 1984).  
Immunohistochemical studies have identified numerous NPY-immunoreactive nerves 
in erectile tissues, with a high density around helicine arteries (Wespes et al, 1988; 
Schmalbruch and Wagner, 1989;Kirkeby et al, 1991). Initially, NPY was suggested to 
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play a role in detumescence (Kirkeby et al, 1991). However, functional studies using 
human corpus cavernosal strips did not support this, as NPY was ineffective 
(Hedlund and Andersson, 1985). Interestingly, intracavernous injection of NPY 
increased ICP and led to penile tumescence in rabbits (Kirkeby et al, 1992). 
 
1.3.4 Angiotensin II (Ang II) 
The renin–angiotensin system (RAS) is a complicated hormonal system. Angiotensin 
II (Ang II) is the main effector of RAS and a regulator of important physiological 
functions. Angiotensinogen is the precursor of all angiotensin peptides, consisting of 
453 amino acids. It is synthesized and released from the liver into the circulation. 
Renin, an acid protease produced by the kidney juxtaglomerular cells, cleaves amino 
acids from the N-terminus of angiotensinogen to generate angiotensin I (Ang I). 
Subsequently, Ang I is converted to the octapeptide Ang II by ACE, which occurs 
primarily in the lung. In addition, the formation of Ang II from Ang I is catalyzed by a 
chymotrypsin-like serine protease, chymase, which is released from mast cells. Ang 
II is metabolized by aminopepsidase A to angiotensin III (Ang III). 
The traditional view of RAS as a systemic endocrine system has been extended in 
the past decade. Many organs and tissues, such as heart, brain, kidney, and blood 
vessels, contain components of RAS, functioning in a paracrine manner, that is 
mediators released/synthesised by the organ and acting locally (Tipnis et al, 2000). 
Tissue RAS synthesizes Ang II locally, which is modulated independently of systemic 
RAS. It plays an important role in the regulation of local tissue functions in addition to 
systemic RAS. The accumulated evidence suggests the existence of RAS in the 
penis. 
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1.3.4.1 Angiotensin II receptors 
Ang II exerts its biological actions mainly through two subtypes of angiotensin 
receptors: type 1 (AT1) and type 2 (AT2). These receptors are seven 
transmembrane-spanning receptors that belong to the G-protein-coupled receptor 
superfamily but only have 34% sequence identity (Mukoyama et al, 1993). AT1 has 
two isoforms: AT1a and AT1b. AT1a is dominantly expressed in the smooth muscle 
and endothelial cells of the blood vessel wall, brain, and many other organs. The 
AT1b receptors are found mainly in the anterior pituitary and adrenal cortex (Gasc et 
al, 1994). Ang II is a potent ligand for AT1, whereas Ang I and Ang III have much 
lower affinity for AT1. The most commonly described physiological actions of Ang II 
are mediated by AT1, including vasoconstriction, cell growth and proliferation, salt 
and water retention, activation of the sympathetic nervous system and stimulation of 
vasopressin. Unlike AT1, which has been extensively studied, the physiological role 
of AT2 is much lesser known. AT2 is dominantly expressed in fetal tissues, which 
dramatically decreased after birth (Shanmugam et al, 1995; Mialn et al 1991). 
Consequently, it is difficult to study the function of AT2 in adult tissues, as 
expression levels are very low. Frequently in experimental settings, blocking AT1 is 
required to reveal the functions of AT2. Studies have shown that the actions of Ang II 
mediated by AT2 are mostly opposite to those of AT1. These physiological 
responses include vasodilatation, antiproliferation, and apoptosis (Zimpelmann et al, 
2001). 
 
1.3.4.2 Ang II signalling  
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Stimulation of AT1 triggers multiple signal transduction processes, leading to a 
variety of (patho) physiological actions. AT1-mediated vasoconstriction occurs 
through both calcium-dependent and independent mechanisms. The classic pathway 
is the G-protein-mediated activation of phospholipase, releasing inositol 
trisphosphate and diacylglycerol, thereby increasing intracellular calcium. Studies 
have also shown that Ang II activates the RhoA/Rho-kinase-mediated calcium 
independent pathway via AT1, leading to the inhibition of myosin light chain 
phosphatase ( Ryan et al, 2004; Ying et al, 2006). 
Another important function of AT1 is to activate nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, increasing reactive oxygen species (ROS) production. 
ROS not only quickly react with NO, to reduce NO bioavailability, but it also 
stimulates RhoA/Rho-kinase activity (Jin et al, 2006; Burnett et al, 2006). Moreover, 
AT1 initiates intracellular signalling cascades that are important in the regulation of 
cell growth and proliferation through receptor tyrosine kinases (e.g., epidermal 
growth factor receptors, platelet-derived growth factor receptors, and insulin 
receptors), non-receptor tyrosine kinases (e.g., Src and Janus kinase), and mitogen 
activated protein kinases (Nakashima et al, 2006; Touyz et al, 2002).  
AT2-mediated vasodilatation is observed in both large conduct vessels, such as the 
aorta, and small resistance arteries including mesenteric, coronary, and uterine 
arteries. The activation of AT2 enhances NO production through modulation of 
endothelial eNOS protein expression and/or phosphorylation at positive regulatory 
sites on eNOS (Yayama et al, 2006). 
 
1.3.4.3 The physiological role of Ang II in the penis 
Ang II exerts its physiological function/action in the corpus cavernosum in a 
paracrine manner, since the octapeptide is produced by the human corpus 
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cavernosum and acts locally (Kifor et al, 1997). Angiotensin peptides, including Ang I 
and Ang II, has been detected in human CCSM and endothelial cells (Kifor et al, 
1997). Becker et al. (2001) reported that Ang II levels were 30% higher in the 
cavernous blood than in systemic blood. A comparison of the different penile phases, 
i.e. flaccidity, tumescence, rigidity, and detumescence, revealed that Ang II levels 
were significantly higher during detumescence (Becker et al, 2001). This finding 
highlights the importance of Ang II when the penis is not erect. The distribution 
pattern of Ang II containing cells has been identified in the endothelial and CCSM 
cells of the rat penis ((Kifor et al, 1997). Ang II binding sites have also been 
determined in rabbit corpus cavernosum by autoradiography. Support for the location 
of Ang II in the corpus cavernosum has been provided by immunostaining for ACE 
using dog corpus cavernosa, which found the enzyme in the endothelial cells 
(Iwamoto et al, 2001).  
The functional response of Ang II has been reported; it was found to cause a 
profound contraction of isolated rabbit cavernosal muscle strips that was much 
stronger than Ang I (Park et al, 1997). In addition, they found ACE inhibition 
markedly reduced the contractile response elicited by Ang I, indicating that Ang I is 
converted to Ang II by ACE located in the cavernosal tissue (Park et al, 1997). 
They also determined that Ang II-induced CCSM contraction was via AT1 receptor 
activation and not AT2 (Park et al, 1997). These observations have been confirmed 
using canine CCSM tissue, in addition, the effect of Ang II was augmented by NOS 
inhibition (Comiter et al,1997). Blockade of AT1 receptors also significantly reduced 
adrenergic agonist- and electrical field stimulation induced contractions, suggesting a 
possible role of Ang II in regulation of a-adrenergic activity in the penis. These data 
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are in line with previous findings that suggest RAS has a stimulatory influence on the 
sympathetic nervous system (Brasch et al,1993). 
It would seem, therefore, that Ang II is a potent constrictor of CCSM and thus an 
essential modulator of erectile function. This role is clear to see following in vivo 
injections of Ang II into the cavernosal body of anesthetized dogs, which terminated 
spontaneous erections (Kifor et al, 1997). Interestingly, intracavernosal injection of 
losartan, the AT1 antagonist, increased the ICP in a dose dependent manner, 
resulting in penile erection (Kifor et al, 1997). These data reinforce the notion that the 
physiological role of Ang II is to increase CCSM tone to ensure the penis is kept in a 
flaccid state.  
 
1.3.5 Reactive oxygen species, Ang II and nitric oxide  
Molecular oxygen (dioxygen) is utilized by all mammalian cells, there being more 
than 200 enzymes that have oxygen as one of its substrate (Malmstrom, 1982). The 
metabolism of oxygen inevitably generates ROS. Amongst the ROS family are 
superoxide (O2
•-
), hydrogen peroxide (H2O2), hypochlorous (HOCl), hydroxyl radicals 
(OH•), reactive aldehydes and lipid radicals (Hensley et al 2000; Shah & Channon, 
2004). There are also products from reactions between ROS and NO, for example, 
peroxynitrite (ONOO-) (Jeremy et al, 2000; Patel et al, 2000). Sources of ROS 
include NADPH oxidase, the mitochondrial electron transport chain, xanthine 
oxidase, NOS, cyclooxygenase, lipoxygenase, haemoxygenases and haemoprotien, 
as well as by redox cycling of small molecules, hypoxia-re-oxygenation, auto-
oxidation, hypoxia and oxygenation of haemoglobin. Oxidative injury, i.e. OS, occurs 
when the oxidative burden of the body exceeds its antioxidant capacity. Lipid 
peroxidation, protein oxidation, DNA oxidation, decreased synthesis and 
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bioavailability of eNOS and nNOS and the up-regulation of pro-inflammatory 
cytokines, growth factors and tissue-specific receptors have all been implicated in 
this form of injury (Slater, 1984). Ang II is a potent stimulator of the smooth muscle 
enzyme NAD(P)H oxidase, which stimulates the production of ROS such as  •O2
– 
(Touyz, et al 2001). In fact, in human blood vessels the membrane associated 
NAD(P)H oxidase is thought to be the principle source of basal and Ang II-induced 
•O2
–, and is implicated in virtually every cardiovascular disease (CVD) (Cai et al, 
2003; Jeremy et al, 2004; Puntmann, et al, 2005). The expression of NADPH 
oxidase is upregulated by a disparate number of factors implicated in vascular and 
erectile pathology. These include; endotoxins, peptide growth factors, endothelin-1, 
Ang II, thromboxane A2, hypoxia and shear stress (Muzaffar et al, 2005).   
•O2
– exerts a number of pathological actions that range from increased cell 
proliferation, apoptosis of endothelial cells, signal transduction activation, calcium 
mobilization and vasoconstriction (Young & Woodside, 2001; Jeremy et al, 2004). 
The up regulation of  •O2
–, production by Ang II in endothelial and vascular smooth 
muscle is thought to directly contributes to Ang II-induced smooth muscle contraction 
(Kawazoe et al, 2000). •O2
– also reacts readily with NO to produce ONOO- and other 
ROS (Patel et al, 2000). These reactions have two main consequences: 1) a 
reduction of NO bioavailability and 2) the generation of other toxic radicals (Folkerts 
et al, 2001; Dweik, 2005). An increase in the vascular formation of •O2
– and H2O2 has 
been reported in atherosclerosis, diabetes mellitus (DM), dyslipidemia, smoking, and 
hypertension (Jeremy et al, 1999 & 2004; Li et al, 2004).  
 
 
 
 
 48 
 
1.4 Erectile dysfunction (ED) 
ED is defined as the persistent inability to maintain or achieve a penile erection 
sufficient for satisfactory sexual performance. It is a widespread problem affecting 
many across all age groups. The anxiety and psychological burden can affect the 
well being of sexually active men and seriously impinge on their quality of life. Over 
30 million men suffer from ED in the USA (Lue et al, 2000) and the prevalence is 
predicted to rise considerably over the next 25 years, impacting on 300 million men 
worldwide by 2025 ( Ayta et al, 1999). 
ED is often associated with CVD (Hafez, 2005), including DM (McCulloch et al, 
1980), hypercholesterolemia (HcH) (Martin-Morales et al, 2001; Wei et al, 1994), 
hypertension (Martin-Morales et al, 2001), and smoking (Jeremy and Mikhailidis, 
1998), all of which are increasing globally. Although, the aetiology of ED is not fully 
understood, in the last 4 decades the elucidation of many aspects of the erectile 
mechanism has ushered in a new era of therapeutic options for erectile disorders 
(Mersdorf, 1991). New insight into erectile neurotransmission (Andersson et al, 
1994) and the discovery of the importance of the NO pathway (Ignarro, 1990), has 
resulted in a rational alternative for treating ED (Andersson, 2011). 
As discussed, Ang II is the primary effector of RAS, it is a multifunctional hormone 
that plays an important role in vascular function and the beneficial effect of Ang II 
receptor blockers in CVD (hypertension, heart failure and stroke) is well known 
(Schiffrin et al, 2000). 
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Since Ang II and NO signalling pathways mutually regulate each other by multiple 
mechanisms ( Yan et al,  2003) and the corpus cavernosum is essentially a modified 
blood vessel, it is reasonable to assume that Ang II has a role to play in ED. 
1.4.1 Aetiology of erectile dysfunction  
ED can be classified as organic or psychogenic (Melman & Gingell, 1999). The 
former constitutes around 80 % of causes, which include vasculogenic and 
neurogenic subgroups. However, it is becoming increasingly apparent that the 
aetiology of a significant proportion of these patients is of mixed origin. (1st Latin 
American Erectile Dysfunction Consensus Meeting, 2003). 
 
1.4.1.1 Psychogenic ED 
Previously, psychogenic impotence was believed to be the most common type, with 
90% of impotent men in this group. This was exemplified in the 1960’s and 1970’s 
when ED was generally managed by psychiatrists, and thought to be a psychological 
disorder (Morgantaler, 1999). However, since the introduction and improvement of 
diagnostic aids, and the use of intracorporal vasoactive drugs as therapeutic agents, 
this view is no longer held. 
Sexual behaviour and penile erection are controlled by the hypothalamus, the limbic 
system, and the cerebral cortex (Dean et al, 2005).Therefore, stimulatory or 
inhibitory messages can be relayed to the “spinal erection centres” to facilitate or 
inhibit erection. Two possible mechanisms have been proposed to explain the 
inhibition of erection in psychogenic ED: direct inhibition of the spinal erection centre 
by the brain as an exaggeration of the normal suprasacral inhibition and excessive 
sympathetic outflow, which increases CCSM contraction and prevent its relaxation, a 
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process required for penile erection (Steers, 1990). Psychogenic ED is more 
prevalent in younger men, accounting for up to 50% of cases in under 40 years old 
(Caskurlu et al, 2004), compared to around 10% in those over 50 years old (Slag et 
al, 1983). It can be further classified into generalized and situational (Rosen, 2001), 
or primary and secondary (lifelong or acquired) (Anonymous, 1st Latin American 
Erectile Dysfunction Consensus Meeting, 2003). The common disorders associated 
with this type of ED include anxiety, psychotic disorders, and depression (Farre et al, 
2004). Antidepressant can also further exacerbate ED in these patients (Nurnberg et 
al, 2002). 
 
1.4.1.2.Vasculogenic ED 
Vasculogenic ED (VED), involving arteriogenic or veno-occlusive impairment, is the 
commonest underlying pathogenesis in ED. This is exemplified by the strong 
correlation between VED and CVD and its common risk factors. VED is more 
prevalent in those with coronary artery disease (CAD) (Kloner et al, 2004). Moreover, 
the severity seems to correlate with the number of coronary arteries affected 
(Greenstein et al, 1997). The Massachusetts Male Aging Study (MMAS) revealed 
that cigarette smoking doubled the risk of significant VED after 8-10 years, with 
slightly lower risks associated with hypertension, and dietary intake of cholesterol 
and unsaturated fat (Feldman et al, 2000). Atherosclerotic lesions were 
demonstrated in the iliac arteries of cholesterol-fed rabbits that developed 
subsequent impairment of erectile function (Azadzoi & Goldstein, 1992). Diabetic 
men are similarly at risk of developing VED (Feldman et al, 1994; Romeo et al, 
2000), which manifests in over 50% of men 60 years old (Romeo et al,2000). In one 
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report, diabetic and older men were found to have a high incidence of fibrotic lesions 
in the cavernous artery, with intimal proliferation, calcification and luminal stenosis 
(Michal et al, 1982). 
VED is now a recognized marker for vascular disease, which may not have 
manifested clinically yet (Sullivan et al, 1999; Montorsi et al, 2003; Kaiser et al, 
2004;). Bocchio et al (2005) demonstrated that the carotid intima-media thickness, a 
marker of atherosclerosis, correlated significantly with the severity of VED in 270 
men who had vascular risk factors but no clinical evidence of atherosclerotic 
disease. Equally, impaired endothelium-dependent, and independent, vasodilatation 
of the peripheral vasculature in men with VED without clinical CVD has also been 
demonstrated (Kaiser et al, 2004). Montorsi et al, (2003) also recognised VED as a 
surrogate marker for CAD. They reported that of the 300 patients presenting with 
acute chest pain associated with angiographically proven CAD, 67% had developed 
VED prior to cardiac symptoms, at a mean interval of 38.8 months. It is now clear 
that the common denominator that links VED with CAD is endothelial dysfunction 
(Sullivan et al, 1999).  
 
1.4.1.3 Neurogenic ED  
Approximately, 10-19% of ED is of neurogenic origin (de Tejada Saenz et al, 2005). 
In fact, if one was to include, iatrogenic causes and mixed ED, the prevalence of 
neurogenic ED is probably much higher. While, the presence of a neurogenic 
disorder or neuropathy does not exclude other causes, confirming ED is indeed of 
neurogenic origin can be challenging. Common causes include Parkinson disease, 
Alzheimer disease, epilepsy and cerbrovascular events (Lue, 2001). ED in these 
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conditions tend to be manifested at the initiation of the erectile response. The effect 
of Parkinsonism is thought to be due to an imbalance in the dopaminergic pathway 
(Lue et al, 1992). 
In men with spinal cord injuries, their erectile function depends largely on the nature, 
location and extent of the spinal lesion. In addition to ED they may also have 
impaired ejaculation and orgasm. Reflexogenic erection is preserved in 95% of 
patients with complete upper cord lesions, whereas only about 25% of those with 
complete lower cord lesion can achieve an erection (Eardley et al, 1991).The close 
association/location between cavernous nerves and pelvic organs, can mean that 
surgery on these organs is a frequent cause of ED, which is very common after 
radical prostatectomy (27-75%) (EAU guideline, 2010). However, nerve sparing 
surgical techniques/procedures can reduce the risk of ED significantly (Hatzichristou 
et al, 2004). Pelvic fracture can result in ED due to cavernous nerve injury or 
vascular insufficiency or both. Diabetic peripheral and autonomic neuropathy is now 
a well recognized disease process that also can lead to ED (Colakoglu et al, 1999; 
Brown et al, 2005). 
 
1.4.1.4 Endocrinological ED  
Between 2% and 23% of men with ED have an underlying endocrine disorder 
(Morales & Heaton, 2003), although it is commonly unclear whether it is the primary 
aetiology (Salonia et al, 2003). 
Hypogonadism is not an infrequent finding in ED. Androgens influence the growth 
and development of the male reproductive tract and secondary sex characteristics; 
their effects on libido and sexual behaviour are well established. In a review of 
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published articles from 1975 to 1992, Muligan and Schmitt (1993) concluded that 
testosterone enhances sexual interest, increase the frequency of sexual acts and 
increase the frequency of nocturnal erection. The suggested underlying 
pathogenesis includes increased smooth muscle apoptosis, increased build up of 
penile connective tissue, and reduced eNOS expression (Salonia et al, 2003). 
Hyperprolactinemia whether from a pituitary adenoma or drug treatment, resulted in 
both reproductive and sexual dysfunction. Symptoms included loss of libido, ED, 
gynecomstia and infertility. It is also associated with low testosterone levels, which 
appears to be secondary to the inhibition of gonadotropin-releasing hormone 
secretion due to the elevated prolactin level (Leonard, 1989). 
 
1.4.1.5 Drug-induced ED 
The incidence of drug related ED has been reported to be as high as 25% (Slag et 
al, 1983). However, this is complicated by the fact that most patients have an 
ongoing disease process, warranting the medication. Drugs that affect the neural, 
vascular or endocrine system, may lead to ED (Thomas, 2002). The commonest 
recognized drug-related ED association is caused by antihypertensives, including 
thiazide and β-blockers (Neaton et al, 1993). It is presumed that α and β blockers 
cause ED by disturbing the autonomic pathways involved in the erectile response 
(Thomas, 2002). Thiazides probably exacerbate ED by reducing blood flow to the 
corpora as a result of reducing systolic blood pressure (Gingell, 2004). 
 
1.4.2 Oxidative stress (OS) in ED 
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The role of OS in ED has been the subject of several studies (Beckman & Koppenol, 
1996; Agarwal et al, 2006). It is known that oxidative products stimulate the 
production of transforming growth factor-b1 (TGF-b1) and up-regulate fibronectin 
gene expression, which have a detrimental effect on the erectile response. Thus, 
treatment with antioxidant agents are beneficial in reducing ED. Barassi et al (2009) 
noted that plasma reactive oxygen metabolite concentrations were higher and 
plasma total antioxidant status was lower in patients with arteriogenic ED compared 
to those with non-arteriogenic ED. In addition, antioxidant treatment was found to 
correct OS in the former group and improve their condition. Another feature of these 
drugs is that they reduce erectile tissue fibrosis, often associated with ED (Agarwal 
et al, 2006). 
OS also plays a role in NO metabolism/function, since it counteracts NO-mediated 
relaxation of intracavernous arteries and CCSM. This is supported by the finding that 
•O2
– destroys NO faster than its natural degradation rate, limiting its bioavailability 
(Kinlay et al, 2004). Additionally, NO has been shown to decrease the adhesion of 
platelets and leucocytes to the vascular endothelial cells (Radomski et al, 1987). A 
reduction in NO concentration was suggested to aggravate the adhesion of these 
cells to the endothelium and release substances such as thromboxane A2, 5-HT and 
leukotrienes leading to vasoconstriction, exacerbating ED (Jeremy et al, 2000). 
 
1.4.3 Partial bladder out flow obstruction and ED  
It is well recognized that the incidence of ED in men increases with age (Panser et 
al, 1995) as does the incidence of benign prostatic hypertrophy (BPH). It is, 
therefore, likely that some men presenting with symptomatic BPH will have varying 
degrees of ED, purely on the basis of their age. However, it is also possible that 
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severe urinary symptoms secondary to BPH might be associated with ED as a result 
of sleep disturbance, psychological anxiety and perhaps even a physiological effect 
from the development of BPH. Although the prevalence of ED and ejaculatory 
dysfunction are similar (~ 50 % of men aged ≥ 50 years) and increase with age, these 
conditions are not inevitable consequences of aging (Rosen et al, 2003). 
In addition to age and Lower Urinary Tract Symptoms (LUTS) other co morbidities 
described previously, (e.g. DM, hypertension, heart disease) are also risk factors for 
ED (Thompson et al, 2005).  
Several clinical studies have demonstrated a relation between LUTS and ED. 
Namasivayam et al (1998) evaluated 168 men attending the prostate clinic for both 
LUTS and ED, they found that men with LUTS and BPH were more likely to suffer 
with symptoms of ED than those without prostatic symptoms. Data from the USA 
BPH Registry provided additional evidence of the significant association between 
LUTS and ED. As the severity of LUTS increased, so did the severity of ED (Rosen 
et al, 2009). Not surprisingly, these results support previous studies highlighting 
LUTS as an independent risk factor for ED (Rosen et al, 2003; Balnker et al, 2001).  
 
1.4.4 The role of Ang II in ED 
There is evidence that Ang II levels in the cavernous blood of men with organogenic 
ED is higher than in men with psychogenic ED or healthy subjects (Becker et al , 
2001). This observation is supported by another study, which showed that 
angiotensin converting enzyme (ACE) activity in cavernous blood from diabetic 
patients with organogenic ED was higher than patients with psychogenic ED. 
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Interestingly; there was no difference in ACE activity in the systemic blood from both 
patient groups (Hamed et al, 2003). 
In animals, ACE mRNA expression was up-regulated in a rat model of arteriogenic 
ED, whilst, expressed at very low levels in control rat penis (Lin et al, 2001). Other 
studies have shown that inhibition of ACE and AT1 improves erectile function, 
demonstrating the pathological effects of Ang II. Treatment with the ACE inhibitor 
captopril partially reversed ED and decreased blood pressure in stroke-prone 
spontaneously hypertensive rats (SHR) (Dorrance et al, 2002). One proposed 
mechanism for hypertension-associated ED in SHR is that Ang II causes vascular 
remodeling in the penis. Enalapril, another ACE inhibitor, significantly reduced 
vascular resistance in isolated penile vascular beds (Hale et al, 2001).  
Treatment with the AT1 blockers candesartan and losartan not only lowered the 
blood pressure but also prevented the adverse morphology changes in penile tissue 
of SHR. Moreover, combination therapy of losartan and sildenafil, further improved 
penile structure when compared with monotherapy with sildenafil or losartan alone, 
this response was thought to be due to an increase in endothelium-dependent 
relaxation (Toblli et al, 2007). 
It is plausible that the prevention of ED by blood pressure lowering drugs may be 
secondary to the correction of hypertension. However, in their study Jin et al (2008) 
found that apocynin treatment only slightly reduced blood pressure, whereas it 
restored most of the erectile function in an Ang II-infused hypertensive rat model. 
This suggests that blood pressure control may not be the only target to improve 
erectile function in these rats. This notion is supported by studies that compared the 
effects of AT1 blockers on erection with other blood pressure-reducing agents. 
Neither amlodipine, (a calcium antagonist), nor hydralazine, (a vasodilator), showed 
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any improvement on penile structure in SHR, despite similar blood pressure lowering 
action to that of AT1 blockers (Tobil et al, 2004; Mazza et al, 2006). Similarly, clinical 
data suggest that antihypertensive drugs such as diuretics, β-adrenergic antagonists, 
and calcium blockers either have no effect or worsen erectile function, while AT1 
blockers may have beneficial effects (Fogari et al,2002; Manolis et al, 2008). 
The signalling pathway activated by Ang II in the penis and the role of Ang II in the 
development of ED has been investigated in vivo by Jin et al (2008). They found 
that, chronic infusion of exogenous Ang II for 4 weeks induced ED in Sprague–
Dawley rats. It was suggested that the excessive Ang II significantly increased 
NADPH oxidase protein expression as well as NADPH oxidase-dependent ROS/•O2
– 
generation in penile tissue isolated from Ang II-infused rats, which would 
undoubtedly lead to CCSM constriction and ultimately ED. 
 
DM is a major risk factor for ED (Ahn et al, 2007; El-Sakka et al, 2007). Recent 
evidence suggests that inhibition of RAS improves cardiovascular function in DM. 
The effect of AT1 blockers on ED was investigated in streptozotocin-induced diabetic 
rats (Chen et al, 2007). Similar to the human studies, Ang II levels were elevated in 
the penile tissue of these animals. Erectile frequency induced by apomophine and 
erectile responses to the stimulation of major pelvic ganglion were significantly 
increased by the AT1 blocker valsartan, whereas another antihypertensive drug, 
spironolactone (an aldosterone receptor antagonist), did not improve erectile function 
in diabetic rats. These observations confirm that an increase in Ang II is a major 
contributor for DM associated ED. 
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1.4.4.1 Clinical evidence of Ang II blockade in ED 
Whilst some antihypertensive drugs may worsen erectile function, many clinical 
studies suggest those that target RAS can be beneficial or have no significant 
negative impact on erectile function and sexual activity (Doumas et al, 2006). 
Initial studies of RAS intervention were focused on its effects on sexual activity. In a 
study of 164 hypertensive men with ED, 12-week therapy with losartan significantly 
improved sexual satisfaction and sexual activity; with no effect on those without a 
previous history of ED (Llisterri et al,2001). In a randomized, double-blind, crossover 
study, the effects of the ACE inhibitor lisinopril and the β-blocker atenolol were 
compared in non-treated hypertensive men. During the initial 4 weeks of treatment 
both lisinopril and atenolol reduced sexual function. However, those on prolonged 
lisinopril treatment (16 weeks) recovered sexual activity, which was not the case for 
those on prolonged atenolol treatment (Fogari et al, 1998). 
Several clinical studies have shown that inhibition of AT1 and ACE improves erectile 
function. In a recent study, more than 1,000 hypertensive patients with hypertension 
and metabolic syndrome were enrolled for treatment with the AT1 blocker irbesartan 
alone or irbesartan with hydrochlorothiazide (a diuretic). At the end of 6 months 
those treated with irbesartan or irbesartan/hydrochlorothiazide, had a significant 
improvement in erectile function along with increased sexual desire and sexual 
contact (Baumhakel, 2008). Interestingly, those who received prior antihypertensive 
treatment with calcium channel blockers, diuretics or antidiabetic drugs, and statins 
had a negative influence on erectile function, whereas α-blockers, β-blockers, and 
ACE inhibitors did not affect erectile function. Although the mechanisms underlying 
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the positive effects of ACE and AT1 inhibitors on erectile function in humans are not 
clear, it seems that blood pressure reduction in itself is not enough to improve 
erectile function. This is supported by many studies, which have shown that other 
classes of antihypertensive drugs are not as beneficial (Manolis et al, 2008). Instead, 
it is more likely that the improvement of endothelial function by ACE and AT1 
inhibitors contribute significantly to the recovery of erectile function. This is 
consistent with the finding that ACE and AT1 inhibitors have been shown to increase 
eNOS mRNA   and protein expression and reduce ROS generation in patients with 
CVD, leading to an increase in NO bioavailability and thus smooth muscle relaxation 
(Billups et al, 2005). 
 
1.5 Hypotheses: Angiotensin II, oxidative stress and NO/cGMP interact and 
play a pivotal role in the normal and pathological erectile process. 
Ang II has been implicated in the termination of penile erection. This study 
investigates whether this process involves Ang II-mediated CCSM contraction and 
the development of OS interacting with NO/cGMP-mediated relaxation, the salient 
feature of penile erection. Moreover, whether the relationship between these 
mediators are disturbed in PBOO, a known model of ED, where NO bioavailability is 
reduced. I will evaluate further and test the hypothesis that inhibition of Ang II and 
OS and the preservation of the NO/cGMP pathway will have a beneficial effect on 
CCSM function using tissue from human and experimental animal models.   
 
1.5.1 Aim 
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1) To characterise the effect of Ang II on CCSM function using exogenous Ang II and 
its antagonists and inhibitors of OS in human, as well as control, and PBOO rabbit 
models using organ bath methodology. In addition, the presence and distribution of 
Ang II within corpus cavernosal tissue, will be determine using 
immunohistochemistry. 
 
2) To determine whether the beneficial actions of losartan (AT1 receptor antagonist) 
on CCSM function, is due to a pro-tumescence effect by inhibiting Ang II-mediated 
CCSM contraction. 
 
 
3) To investigate whether the NO-mediated CCSM relaxation associated with PBOO 
is impaired and the effect of in vitro losartan treatment. 
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CHAPTER 2 
______________________________________ 
 
 
 
 
MATERIALS AND METHODS 
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2.1 Purchase and maintenance of rabbits  
Adult male New Zealand White rabbits weighing between 2.5 - 3.0 kg were 
purchased from Harlan UK (Bicester, Oxford), a UK Home Office accredited source.  
These normal healthy rabbits were kept in the animal house for at least a week 
before the start of the study to acclimatise them to the local surroundings. The 
rabbits were exposed to a 12-hr on and 12-hr off light/ dark cycle during that week 
and to the end of the study, prior to their sacrifice. All animal were fed ad libitum on 
rabbit maintenance, standard plain diet (Scientific Diet Supplies, Whitham, UK) and 
allowed free access to water.  
 
2.2 Induction of partial bladder outlet obstruction (PBOO) in rabbits 
Animal models of PBOO are well established (Khan et al, 1999; Calvert et al, 2001a; 
Lin et al, 2008; Beamon et al, 2009) and can mimic BPH and reproduces the 
urodynamics and structural changes in bladder pathophysiology (Calvert et al, 2001a 
; Beamon et al, 2009).  
To create PBOO, each rabbit received a general anaesthetic (1-2% halothane in O2) 
and was then placed on a heating pad regulated at 370C.  
The abdominal fur was shaved and a urinary balloon catheter (Foley, C.R. Bard 
international Ltd, Crawley, UK) size 8 Fr gauge was inserted uretherally via the penis 
into the bladder and the balloon inflated. A lower midline laparotomy was then 
performed to expose the bladder, unlike man the whole of the rabbit bladder lays 
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superficially within the peritoneum. The bladder neck was identified and a 2-0 silk 
ligature was then placed around the urethra as distal as possible below the bladder 
neck but above the entrance of the prostatic ducts into the urethra. The silk ligature 
was placed snugly, without any tension, around the urethra so that the catheter can 
be easily removed without any resistance. This procedure was found to be 
reproducible and required approximately 20 min to complete. 
At the end of the operation the peritoneum was irrigated liberally with about 50 ml of 
sterile normal saline, to prevent small bowel obstruction secondary to adhesion 
formation. The urinary balloon catheter was then removed and the laparotomy 
incision closed in layers. The peritoneum was closed with continuous 2-0 vicryl, 
rectus muscles were approximated using interrupted 2-0 vicryl sutures, rectus sheath 
closed using continuous 2-0 vicryl. The skin was closed with continous subcuticular 
2-0 prolene sutures. Local anaesthetic (lignocaine 1%) was then applied to the 
wound site and the animal allowed to recover (Khan et al, 1999).  
Pain medication (buprenorphine, 0.1 mg/kg im, twice daily for 2 days) and antibiotics 
(enrofloxacin, 10 mg/kg im, twice daily for 5 days pre- and post-operatively) was 
administered to each rabbit. Sham-operated rabbits underwent the same surgical 
procedure without tying the ligature around the urethra.  
All procedures were conducted under an approved Home Office Project Licence.  
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2.3 Acquisition of control, sham-operated and PBOO rabbit penile 
tissues  
After 8 weeks the sham-operated and PBOO rabbits were killed by cervical 
dislocation (using a method permitted by the Home Office). The penis was rapidly 
excised from each rabbit and placed in cold oxygenated Krebs solution at 40C and 
transported to the laboratory for organ bath experiments (Thompson et al, 2001).  
The Krebs solution was made up of sodium chloride (NaCl) 133 mM, sodium 
bicarbonate (NaHCO3) 16.4 mM, magnesium sulphate (MgSO4) 0.6 mM, potassium 
chloride (KCl) 4.7 mM, calcium chloride (CaCl2) 2.5 mM, monosodium phosphate 
(NaH2PO4) 1.4 mM and glucose 7.7 mM with a pH of 7.4. 
Tissue preparations were investigated on the same day within 1h of acquisition.  
Twenty animals were used for the control rabbit study (see Chapter 3). In other 
experiments 20 rabbits underwent PBOO with 12 age-matched, sham-operated 
rabbits (see Chapter 5).  
 
2.4 Acquisition of human penile tissues for experiments 
Human penile organs were obtained from 35 patients undergoing gender 
reassignment surgery at Charing Cross Hospital, London UK. Ethics approval was 
obtained (Riverside Ethics Committee Chelsea & Westminster Hospital, London) and 
all patients gave their informed consent prior to surgery. The patients undergoing 
gender reassignment surgery were on oestrogen treatment for approximately two 
years. However, this was discontinued for at least 2 months prior to surgery and 
experiments were conducted within 24 h of tissue acquisition (see Chapter 4).  
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Mirone  et al, (2000) has reported that corpus cavernosal tissue obtained from 
gender reassignment surgery constitute a reliable/viable source of human tissue with 
functional integrity. This tissue can be used for up to four days to evaluate drug 
activity or to study corpus cavernosal pathophysiological mechanisms; a conclusion 
based on unchanged responses during this time, to chemical stimuli such as 
phenylephrine (PE), Ang II and potassium chloride (KCl), as well as acetylcholine 
(ACh; endothelium-dependent) and sodium nitroprusside (SNP; endothelium-
independent), mediators of smooth muscle relaxation. 
 
2.5 Organ bath experiments 
2.5.1 Materials 
The following chemicals were purchased from Sigma Chemical Co. (Poole, UK): KCl, 
atropine hydrochloride, guanethidine, indomethacin, phenylephrine (PE), 
diphenylene-iodoniuym chloride (DPI), superoxide dismutase (SOD), 4-hydroxy-3-
methoxyacetophenone (apocynin), human angiotensin II (Ang II), PD123,319, L-NG-
nitroarginine (L-NAME). Angiotensin II antiserum (T-5001), host guinea pig for 
immunohistochemistry was purchased from Bachem (Bubendorf, Switzerland). 
Rabbit anti-guinea pig peroxidase conjugate antibody, mouse monoclonal anti CD34 
and normal goat IgG was purchased from Dako UK, Ltd (Cambridgeshire, UK).  SNP 
was purchased from BDH Chemical Ltd (Poole, UK. Losartan was a free gift from 
Merck Research Laboratories (New Jersey, USA).  
 
 
 
 
 66 
2.5.2 Organ bath technique 
Before the start of the experiments the buffer reservoir, thermoregulated circuit and 
10 ml organ baths were washed twice with distilled water and Krebs. The buffer 
reservoir was then filled with the Krebs solution. Artery forceps were used to clamp 
the tubes that released Krebs into the organ bath from the reservoir, as well as the 
tubes that drained the buffer way. The apparatus was calibrated using the chart 4 
software the system with a 4g weight. 
 
The corpus spongiosum and urethra were excised and the corpus cavernosal muscle 
isolated from the surrounding tunica albuginea by careful dissection of rabbit and 
human penis and cut into strips (4-8 pieces) of approximately 1x3x1 mm and 5x5x6 
mm, respectively. The size and weight of normal, sham-operated and PBOO rabbit 
cavernosal strips from each experimental group were similar.  
Each tissue strip was attached at one end to the horizontal section of an L-shaped 
stainless steel rod with a piece of string. This anchorage was regarded as the tissue 
“fixed point” during the experiments. A piece of string was also tied to the other end 
of the tissue, which was long enough to be rapped around a hook attached to a 
transducer connected to a  Grass Polygraph (model 7D; Astro-med Grass, Slough 
UK). This was the “dynamic point” of the set up, as either relaxation or contraction of 
the strip will cause a change in the tension, which was recorded by the polygraph. 
The tissue strips were mounted vertically into the organ baths and immersed into 
Krebs solution at pH 7.4, maintained at 370C by the thermoregulated circuit and 
bubbled with a mixture of 95% O2 - 5% CO2.          
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A 2g tension was applied to the suspended tissue strips, which were washed twice 
and left for 1h to equilibrate and the tension recorded on the Grass Polygraph. It was 
noticed on some occasions that the tissue tension in the organ bath drop below 2g, 
however no attempt to re-equilibrate the tension was taken, as this might affect 
tissue contractility. The lay out of the apparatus can be seen in Fig 4. 
In some experiments the L-shaped stainless steel rod was also equipped with two 
parallel platinum electrodes. The tissue was strung up the same as before, but 
mounted between these electrodes to allow electrical field stimulation (EFS). A 
stimulation frequency of 8Hz was used in all experiments, since it has been reported 
that this frequency produced the maximum relaxation (32.8%) of human cavernosal 
strips (Lau et al, 2009). 
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Figure 4:  Photograph showing 4 organ baths used to determine corpus cavernosal 
tissue function. 
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2.6 Immunohistochemistry 
Human CC tissue was fixed in formalin and embedded in paraffin wax. Serial 3μm 
tissue sections were cut to allow immunostaining of adjacent sections for Ang II, 
smooth muscle actin and an endothelial marker, CD34. Sections were rehydrated 
and endogenous peroxidase was blocked by 0.5% hydrogen peroxide in methanol. 
Antigen retrieval for Ang II and smooth muscle actin immunostaining was by 
microwaving at 900W for 20 min in Tris-EDTA buffer pH 9. Antigen retrieval for 
endothelial immunostaining was by microwaving at 600W for 10 min in citrate buffer 
pH 6. For smooth muscle actin immunostaining, sections were covered with mouse 
monoclonal anti smooth muscle actin (Dako) at 1:500, followed by anti mouse IgG 
conjugated to horseradish peroxidase using the NovoLink polymer system (Leica). 
For endothelial immunostaining, sections were covered with mouse monoclonal anti 
CD34 at 1:50, followed by anti mouse IgG conjugated to horseradish peroxidase as 
for smooth muscle actin immunostaining. For Ang II immunostaining, sections were 
covered with guinea pig anti Ang II at 1:100 in Tris buffer pH 7.6 for 30 min. After 
washing, sections were covered with rabbit anti guinea pig IgG conjugated to 
horseradish peroxidase at 1:500 for 30 min. After further washing, diaminobenzidine 
and hydrogen peroxide were added as substrates for peroxidase. The sections were 
counterstained with Mayer’s haematoxylin. Control sections had omission of the first 
stage antibody. 
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Chapter 3 
________________________________________ 
 
 
 
 
The interaction between angiotensin II and 
nitric oxide on rabbit corpus cavernosal 
function. 
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3.1 Introduction: 
The regulation of corpus cavernosal smooth muscle tone has been a subject of 
interest due to its importance in the process of penile erection. Most studies have 
focussed on mediators of CCSM relaxation in an attempt to develop new treatment 
strategies for ED and it is from this work the PDE 5 inhibitors have emerged as the 
front line therapeutic option. However, unlike most smooth muscle cells those of the 
corpus cavernosum spend the majority of the time contracted (Chang et al, 2002), 
which keeps the penis in a flaccid state. This is achieved by a variety of 
vasoconstrictor agents that maintain the balance between CCSM contraction and 
relaxation, as discussed in Chapter 1. Thus, the control of penile tone determines the 
functional status of the penis at any one time, which will range from; detumescence 
and flaccidity to tumescence and erection. 
The vasoconstrictors agents that keep the penis in the flaccid/detumescence state 
are not very well understood. Angiotensin II (Ang II), a known modulator of regional 
blood flow in the vascular bed, is thought to be one such mediator of human CCSM 
contractility and tone (Becker et al, 2001). 
A previous rabbit study demonstrated that Ang II causes a dose dependent 
contraction of CCSM tissue (Park et al, 1997). These authors carried out functional 
characterisation of the Ang II receptors on rabbit CCSM and found that the Ang II 
response was blocked by AT1 but not AT2 receptor antagonist. Although this was a 
very important finding, they did not explore the possible interaction of Ang II with NO 
an important mediator of CCSM relaxation. This was partially addressed in another 
study that examined the effect of the NOS inhibitor, nitro-L-arginine methyl ester (L-
NAME) on the Ang II response using canine CCSM (Comiter et al, 1997). In that 
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study Ang II again caused a dose-dependent contraction, which was augmented by 
L-NAME. The authors also noted that adding SNP at the peak of the Ang II 
contraction caused CCSM relaxation. However, this may be a direct effect of SNP-
induced relaxation and not an interaction between Ang II and NO. This study, 
therefore, lacks a true demonstration of an interaction at the receptor level. 
 Thus, in this Chapter the focus will be on the physiological interaction of Ang II/NO, 
together with their relationship with ROS and OS on rabbit CCSM tone. This is 
particularly important, since along with its potent and well defined vasoconstrictive 
action, Ang II has been demonstrated to increase •O2
– production in endothelial cells, 
vascular smooth muscles, adventitial fibroblasts and mesangial cells through 
activation of NADH/NADPH oxidases (Touyz et al ,2002; Pagano et al ,1998; Jaimes  
et al ,1998; Lassègue et al ,2003). In addition, chemical antagonism between •O2
– 
and NO is recognized as a potentially important modulator of vascular reactivity as 
well as a source of ONOO- production, a potent oxidant (Beckman et al, 1990). 
These experiments have the potential to define the physiological role of Ang II in the 
erectile process. 
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3.2 Material and Method: 
 3.2.1 Tissue acquisition 
See Chapter 2 for details of tissue acquisition and experimental procedure. 
 
3.2.2 Ang II response 
In preliminary experiments, multiple application of different concentration of Ang II 
were applied to each rabbit CCSM strip to create a cumulative dose response curve, 
an approach described by Park  et al (1997). Unfortunately, this resulted in an 
undulating curve which was difficult to interpret. It was also noted that repeated 
applications of Ang II caused a marked desensitisation of the functional response 
(i.e. tachyphylaxis), which made the data even more unreliable. This phenomenon 
has been reported by others using isolated human arteries (Hidaka T et al 2005). 
Therefore, to avoid erroneous interpretation of the data, a single dose of Ang II / 
individual tissue, in a dose range of 10-8M – 10-5M was used to minimise the 
development of tachyphylaxis and create each dose response curve. This meant 
each Ang II concentration had to be repeated several times, which was time 
consuming and required the use of many tissue strips.  
 
3.2.3 Effect of Ang II receptor antagonists and L-NAME 
 The effect of Ang II on tissue strips was determined; the tissue was then washed 
over a 30 min period and exposed to either losartan (10-5 M; AT1 antagonist) or 
PD123,319 (10-5 M; AT2 antagonist) for 20 min before repeating the Ang II response. 
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The effect of the vehicle (distilled water for 20 min) on the Ang II response was also 
determined. In other experiments, nitro-L-arginine methyl ester (L-NAME, a nitric 
oxide synthase inhibitor, 10-4 M) was added to the bathing solution for 20 min and 
the effect on the Ang II (10-6 M) response determined. 
3.2.4 Effect of SNP 
 Tissue strips were pre-contracted with phenylephrine PE and cumulative response 
curves were constructed for SNP (3x10-7 - 10-6 M), with each dose only being applied 
when the response had reached a plateau. The tissues were then washed several 
times followed by the addition of losartan to the organ bath for 20 min. The tissues 
were re-contracted with PE and cumulative response curves were again constructed 
for SNP. 
 
3. 2.5 Electrical field stimulation (NANC neurotransmission) 
 In a series of experiments CCSM tissue strips from control rabbits were exposed to 
a mixture of guanethidine (5 x 10-6 M), atropine (10-5 M) and indomethacin (10-6 M), 
added to the bathing solution and left for 20 min. The purpose of this treatment was 
to inhibit the adrenergic, cholinergic and cyclo-oxygenase pathways, respectively, 
leaving the NANC pathway intact. Tissues were then pre-contracted with PE (10-4 M) 
followed by EFS of penile nerves with a Grass S88 (Astro-med Grass, Slough UK) 
stimulator. The stimulator delivered single square waves (duration 0.4 ms; 100V) at a 
frequency of 8.0 Hz in 5 s trains.  
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 3.2.6 Oxidative stress  
3.2.6.1.1 DPI : The effect diphenylene iodonium chloride (DPI, 10-4M, NAD(P)H 
oxidase inhibitor, which inhibits •O2
–  production)  has on the Ang II-induced 
contraction (10-6M) was determined.  
 
3.2.6.2 SOD: The effect superoxide dismutase (SOD, 200 IU/ml; the enzyme that 
accelerates the breakdown of •O2
–) has on the Ang II (10-6M) response was also 
determined. 
 
3.2.6.3 DPI and SNP 
To demonstrate the effect of inhibiting OS on SNP-induced relaxation, DPI and 
losartan were used. SNP cumulative response curves were constructed using rabbit 
CCSM tissue. The tissue was washed several times before the addition of DPI and 
losartan to the organ bath for 20 min and re-contracted with PE and the SNP 
cumulative response curve repeated. 
 
3.2.7.Electrical Field Stimulation (NANC neurotransmission). 
In another series of experiments, the effect OS and AT1 receptor inhibition have on 
NANC neurotransmission was determined. 
The triple blockers were added to the organ bath; tissues were then pre-contracted 
with PE (10-4 M) followed by EFS of penile nerves, which resulted in CCSM 
relaxation. This was followed by the addition of losartan and DPI, which blocked AT1 
receptors and OS, respectively. The tissues were re-contracted with PE and the EFS 
repeated.  
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3.2.8 Statistical Method 
The raw data from Ang II pre- and post-losartan, PD123,319, L-NAME, DPI and SOD 
were expressed as % contraction of the PE contractile response. EFS and SNP 
tissue responses determined pre- and post- losartan, DPI were expressed as % 
relaxation of PE-induced tone. These were analysed and expressed as mean ± SEM 
using Graph Pad Prism 4.0 software (see examples, Tables 1-4). Comparisons of 
the resultant Ang II dose response curves and SNP cumulative dose response 
curves were made using analysis of variance (2 way ANOVA, p < 0.05). Student’s 
unpaired and paired t-test statistical analysis was also determined on the raw data 
by the software package with statistical significance accepted at p < 0.05. The 
individual number of tissue strips used is included in the figure Legends. Strips from 
at least 5 animals were used in each experiment 
 
3.3 Results:  
3.3.1 Ang II and its receptors antagonists on corpus cavernosal smooth 
muscle contraction. 
Ang II caused a dose dependent contraction (10-8M – 10-5M) of CCSM strips. This 
effect was significantly (ANOVA; P < 0.0001) reduced by losartan (Table 1, Figs 5 & 
5a) but not by PD123,319 (ANOVA ; P= 0.79, Table 2, Figs 6 & 6a) , confirming that 
the contractile effect of Ang II  on  rabbit CCSM is mediated mainly by AT1 receptor. 
The addition of water (vehicle) had no effect on Ang II-induce contraction. 
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Table 1: Ang II–induced contraction of corpus cavernosal strips pre- and post- losartan 
 
Strip No. Ang II 
10
-8
M 
               
% PE 
contraction 
Ang II 
10
-8
M post-
los 
% PE 
contraction  
Ang II 
10
-7
M 
                
% PE 
contraction 
Ang II 
10
-7
M 
post-los 
% PE 
contraction  
Ang II 
10
-6
M 
                
% PE 
contraction 
Ang II 
10
-6
M 
post-los 
% PE 
contraction 
 
Ang II 
10
-5
M 
               
% PE 
contraction 
Ang II 
10
-5
M 
post-los 
% PE 
contraction 
1 30.0 20.0 17.0 5.0 39.0 17.0 44.0 22.0 
2 24.0 13.0 11.0 3.0 42.0 10.0 68.0 30.0 
3 12.0 10.0 24.0 12.0 42.0 13.0 61.0 9.0 
4 5.0 4.0 33.0 18.0 42.0 18.0 90.0 18.0 
5 40.0 24.0 50.0 30.0   48.0 30.0 
Mean 22.20 14.20 27.00 13.60 41.2 14.5 62.2 21.8 
Std. 
Deviation 
13.9 7.9 15.3 10.9 1.5 3.7 18.3 8.8 
Std. Error 6.2 3.6 6.8 4.9 0.75 1.8 8.2 3.9 
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Figure 5 
 
 
 
Figure 5: Representative tracing of Ang II (10-7 M)–induced contraction of a corpus 
cavernosal strip pre- and post- losartan. 
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Figure 5a 
 
 
 
 
 
 
 
 
Figure 5a. Ang II-induced contraction of corpus cavernosal strips pre- (■) and post- (▲) 
losartan. *Denotes the data points where there was a significant difference in Ang II-induced 
contraction pre- and post- losartan (Ang II (M): 10-8 p<0.05, 10-7 P<0.0026, 10-6 p<0.0014, 
10-5 p<0.016, paired Student’s t-test, n =4).  
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Table 2: Ang II–induced contraction of corpus cavernosal strips pre- and post- PD123,319 
 
 
 
Strip No. Ang II 
10-8M 
               
% PE 
contraction 
Ang II 
10-8M post-
PD123,319 
% PE 
contraction 
Ang II 
10-7M 
               
% PE 
contraction 
Ang II 
10-7M post-
PD123,319 
% PE 
contraction 
Ang II 
10-6M 
                
% PE 
contraction 
Ang II 
10-6M post-
PD123,319 
% PE 
contraction 
Ang II 
10-5M 
               
% PE 
contraction 
Ang II 
10-5M post-
123,319 
% PE 
contraction 
1 23.0 21.0 41.0 40.0 74.0 65.0 70.0 72.0 
2 20.0 14.0 64.0 60.0 53.0 50.0 82.0 77.0 
3 38.0 44.0 26.0 20.0 42.0 40.0 70.0 72.0 
4 26.0 16.0 28.0 35.0 54.0 58.0 38.0 39.0 
5 14.0 20.0 34.0 27.0 35.0 60.0 48.0 58.0 
6 12.0 24.0 42.0 70.0 15.0 10.0 32.0 21.0 
Mean 22.1 23.2 39.2 42.0 45.5 47.2 56.7 56.5 
Std. 
Deviation 
9.4 10.8 13.8 19.3 19.9 20.2 20.6 22.2 
Std. Error 3.8 4.4 5.6 7.9 8.1 8.2 8.2 9.0 
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Figure 6  
 
 
Figure 6: Representative tracing of Ang II (10-5 M)–induced contraction of a corpus 
cavernosal strip pre- and post- PD123,319. 
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Figure 6a 
 
 
 
 
 
 
 
 
Figure 6a. Ang II-induced contraction of corpus cavernosal strips pre- (■) and post- (▲) 
PD123,319 (n = 6).  
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3.3.2 Effect of L-NAME  
The contractile effect of Ang II was significantly (ANOVA; P < 0.01) enhanced by 
adding L-NAME to the bathing solution (Table 3, Figs 7 & 7a ). 
Table 3: Ang II–induced contraction of corpus cavernosal strips pre- and post- L-NAME. 
Strip No. Ang II 
10-8M 
                 
% PE 
contraction 
Ang II 
10-8M post-
L-NAME 
% PE 
contraction 
Ang II 
10-7M 
                
% PE 
contraction 
Ang II 
10-7M post-
L-NAME 
% PE 
contraction 
Ang II 
10-6M 
                
% PE 
contraction 
Ang II 
10-6M post-
L-NAME 
% PE 
contraction 
Ang II 
10-5M 
                
% PE 
contraction 
Ang II 
10-5M post-
L-NAME 
% PE 
contraction 
1 14.0 33.0 37.0 47.0 40.0 42.0 64.0 66.0 
2 23.0 64.0 27.0 38.0 48.0 55.0 50.0 58.0 
3 24.0 35.0 29.0 36.0 25.0 35.0 32.0 42.0 
4 10.0 13.0 36.0 43.0 47.0 62.0 35.0 39.0 
5 28.0 38.0 27.0 38.0 39.0 58.0 46.0 58.0 
6 27.0 33.0 53.0 59.0 54.0 59.0 80.0 95.0 
7     31.0 47.0 70.0 89.0 
8     54.0 74.0 72.0 76.0 
9     68.0 83.0   
Mean 21.0 36.0 34.8 41.8 45.1 57.2 56.1 65.4 
Std. 
Deviation 
7.3 16.4 9.9 10.6 13.0 15.0 17.9 20.4 
Std. Error 2.9 6.7 4.0 4.3 4.3 5.0 6.3 7.2 
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Figure 7 
  
  
 
 
 
Figure 7: Representative tracing of Ang II (10-6 M)–induced contraction of a corpus 
cavernosal strip pre- and post- L-NAME. 
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Figure 7a 
 
 
 
 
 
 
 
 
Figure 7a. Ang II-induced contraction of corpus cavernosal strips pre- (■) and post- (▲) L-
NAME. *Denotes the data points where there was a significant difference in Ang II-induced 
contraction pre- and post- L-NAME (Ang II(M): 10-8 p<0.047, 10-7 P<0.0047, 10-6 p<0.0006, 
10-5 p<0.0032 , paired Student’s t-test, n =6).  
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3.3.4 SNP and EFS-induced corpus cavernosal smooth muscle relaxation 
The cumulative dose response curve constructed for SNP from rabbit CCSM strips 
was significantly (ANOVA; P< 0.008) enhanced following the addition of losartan 
(Table 4, Figs 8 & 8a). Similarly, EFS-induced relaxation of CCSM strips was 
significantly improved following the addition of losartan (73.9+/-6.1 vs 82.5+/-5.9; P< 
0.033, Fig 9). 
Table 4: SNP-induced relaxation of corpus cavernosal strips pre- and post- losartan. 
 
 
 
 
Strip No. SNP 10
-7 
M 
 
% PE 
relaxation 
SNP 10
-7
 M 
 post –los 
% PE 
relaxation 
SNP 3x10
-
 M 
 
% PE 
relaxation
 
SNP 3x10
-7
 M  
post-los 
% PE 
relaxation  
SNP 10
-6
M 
 
% PE 
relaxation 
SNP 10
-6
M  
post -los  
% PE 
relaxation 
SNP 3X10
-6
 M 
 
% PE 
relaxation 
SNP 3X10
-6 
M  
post-los 
% PE 
relaxation 
1 11.0 13.0 23.0 25.0 46.0 53.0 52.0 76.0 
2 23.0 25.0 41.0 50.0 61.0 62.0 69.0 73.0 
3 15.0 15.0 26.0 26.0 48.0 51.0 49.0 76.0 
4 12.0 15.0 25.0 26.0 47.0 51.0 50.0 75.0 
5 12.0 31.0 26.0 38.0 72.0 80.0 72.0 82.0 
Mean 14.6 19.8 28.2 33.0 54.8 59.4 58.4 76.4 
Std. 
Deviation 
4.9 7.82 7.3 10.9 11.4 12.4 11.1 3.36 
Std. Error 2.2 3.5 3.0 4.9 5.0 5.5 5.0 1.5 
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Figure 8 
 
 
 
 
 
 
 
 
 
Figure 8: Representative tracing of SNP-induced relaxation of a corpus cavernosal strip pre- 
and post- losartan. 
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Figure 8a 
 
 
 
 
 
 
Figure 8a. SNP-induced relaxation of corpus cavernosal strips pre- (■) and post- (▲) 
losartan. * Denotes the data points where there was a significant difference in SNP-induced 
relaxation pre- and post-losartan (SNP (M) 10-6, p<0.024; 3x10-6, p<0.018, paired Student’s 
t-test, n = 5). 
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Figure 9 
 
 
 
 
 
 
 
 
Figure 9. EFS-induced relaxation of corpus cavernosal strips at 8 Hz following the addition 
of guanethidine, atropine and indomethacin, pre- and post-losartan. * Denotes a significant 
difference in EFS-induced relaxation pre- and post- losartan (p < 0.007, paired Student’s t-
test, n = 8). 
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3.3.5 The effect of oxidative stress on Ang II contraction  
 
3.3.5.1 Contraction:  DPI significantly reduced the contractile effect of Ang II 
(68.4+/-6.0 vs 23.00+/-6.0; P = 0.0006, Fig 10). Although, SOD diminished the 
contractile effect of Ang II by 15 %, this was not statistically significant (Fig 11). 
 
Figure 10 
 
 
 
Figure 10. Ang II-induced contraction (10-6 M) of corpus cavernosal strips pre- and post-DPI 
(10-4 M).*Denotes a significant difference in Ang II-induced contraction pre- and post-DPI (P 
= 0.0006, paired Student’s t-test, n = 7).    
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Figure 11 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Ang II-induced contraction (10-6 M) of corpus cavernosal strips pre- and post-SOD 
(200 IU/ml). No significant difference in Ang II-induced contraction pre- and post-SOD (P = 
0.137, paired Student’s t-test, n=7). 
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 3.3.5.2 Relaxation:  The SNP dose response curve was significantly (ANOVA; 
P<0.0001) enhanced following the addition of DPI (Fig 12). 
Following exposure to guanethidine, atropine and indomethacin the EFS-induced 
relaxation of CCSM was significantly enhanced by 36% after the addition of DPI and 
losartan (39.2+/-6.4 vs 61.0+/-4.3; P< 0.007, Fig 13) 
 
 Figure 12 
 
 
 
 
 
Figure 12. SNP-induced relaxation of corpus cavernosal strips pre- (■) and post- (▲) DPI. * 
Denotes the data points where there was a significant difference in SNP-induced relaxation 
pre- and post-losartan (SNP, M), 10-7 p<0.0096; 3x10-7 p<0.01;10-6 p<0.043; 3x10-6 
p<0.018, student paired t test).  
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Figure 13 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. EFS-induced relaxation of corpus cavernosal strips at 8 Hz following the addition 
of guanethidine, atropine and indomethacin, pre- and post-losartan and DPI. * Denotes a 
significant difference in EFS-induced relaxation pre- and post- losartan and DPI (p < 0.007, 
paired Student’s t-test).  
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3.4 Discussion 
The role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology 
of CVD and renal disease is well established (Dzau, 2001). Ang II is a key mediator 
of this system, with actions beyond its hemodynamic and renal activity, influencing 
the function and structure of various tissues in a manner that can promote CVD 
(Dzau, 2001).These include vasoconstriction, vascular and cardiac growth and tissue 
remodeling , OS and inhibition of NO activity (Nickenig & Harrison, 2002). 
Several clinical trials have provided additional evidence of the pathophysiological 
role played by Ang II in the development of CVD (see Chapter 1). 
In fact, drugs that reduced the influence of Ang II have been successfully used to 
treat CVD. For example, ACE inhibitors and AT1 receptors antagonist are beneficial 
therapeutic options for treating hypertension, post myocardial infarction, heart failure, 
and renal dysfunction (Chobanian et al, 2003). 
As the corpus cavernosum consists mainly of endothelial and smooth muscle cells 
and is regarded as a specialized vascular tissue (Becker  et al, 2001), it is likely that 
it is equally vulnerable to the pathological actions of Ang II. 
The possible role of Ang II in ED has previously been explored both in clinical and 
laboratory studies. Ang II levels in the cavernous blood of men with organogenic ED 
was found to be higher than men with psychogenic ED or healthy subjects (Becker et 
al, 2001). While, chronic infusion of exogenous Ang II for 4 weeks induced ED in 
Sprague-Dawley rats (Jin et al, 2008). In addition, intracavernosal injection of Ang II 
terminated spontaneous erection in anesthetised dogs, while the administration of 
losartan induced CCSM relaxation, resulting in penile erection (Kifor et al, 1997).  
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The role of NO and Ang II in penile physiology has been discussed in Chapter 1. 
Interaction between these two important mediators on CCSM function has been 
previously investigated (Schulman et al, 2006). Ang II acts on AT1 and AT2 
receptors to regulate NOS activity and NO production; NO opposes Ang II signalling 
pathways at multiple levels, creating a fine physiological balance between these two 
vasoactive mediators.  
Our finding that Ang II caused a dose dependent contraction of CCSM strips that is 
blocked by losartan but not PD123,319, confirms a previous study also using rabbit 
CCSM tissue, which reported that Ang II acts mainly through AT1 receptor activation 
(Park et al ,1997). Further evidence of the functional interaction between NO and 
Ang II is provided by the findings that blocking the NO pathway with L-NAME, 
potentiated the contractile effect of Ang II, while the NO donor SNP caused a dose 
dependent relaxation which was enhanced with losartan. Also important was the 
finding that AT1 receptor blockade by losartan enhanced EFS-induced CCSM 
relaxation following inhibition of the adrenergic, cholinergic and cyclo-oxyegnase 
pathways. This clearly demonstrates the effect of Ang II on NANC 
neurotransmission.  
Although, aspects of these finding have been reported using canine CCSM tissue 
(Comiter et al, 1996), that study lacked clarity. They did not use the triple blockers 
during their EFS experiments, which left these important contractile pathways 
unopposed, which would undoubtedly influence the results. Furthermore, the SNP-
induced relaxation was tested by adding the NO donor at the peak of the Ang II 
contraction and abolishing the contractile effect of Ang II. From this they concluded 
that there was interaction between NO and Ang II, however, the disappearance of 
the contraction may simply reflect the SNP-induced relaxation and not interplay 
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between NO and Ang II. Here, the evidence that losartan induced an enhancement 
of SNP-mediated CCSM relaxation is scientifically more compelling evidence of the 
NO/Ang II interaction.  
Ang II is an important modulator of vascular smooth muscle cell biology and many of 
its actions are mediated through ROS generation, in particular O2
- (Touyz and 
Schiffrin, 2000). As stated earlier, vascular •O2
– interacts with NO to reduce NO 
bioavailability and generates the potent oxidative ONOO- radical, which plays an 
important role in vascular pathophysiology (Cai and Harrison, 2000; White et al, 
1994). The cellular source of vascular •O2
– vary in different vessel types, most 
studies have shown a membrane-associated oxidase that is stimulated by NADH or 
NADPH, which is consistent with NAD(P)H oxidase being an important source of •O2
– 
production in human, as well as animal models (West et al, 2001). 
Not surprisingly, Ang II is a potent stimulator of NAD(P)H oxidase, whereby short 
term exposure to Ang II enhance NAD(P)H oxidase activity (Cruzado et al, 2005). 
DPI the NAD(P)H oxidase inhibitor was found to markedly decreased Ang II-
mediated  contraction of human arteries. The same study showed an increase in 
ROS generation after 40 minutes exposure to Ang II using fluorescent microscopy. 
Taken together, these findings confirm that the contractile effect of Ang II, at least in 
part, is due to ROS/•O2
– generation (Puntmann et al, 2005).  
It appears that tunica media and adventitia are the predominant vascular areas for 
basal •O2
– production, however, in disease states such as DM, endothelial production 
is significantly increased (Guzik et al, 2002; Mollanau et al, 2002). This maybe a 
feature of diabetic ED and explain why Khan et al, (2001b) found that the impaired 
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relaxation of CCSM from diabetic rabbits was improved by SOD (the enzyme that 
accelerates that break down of O2
-  to H2O) .  
We have shown a marked reduction in Ang II-induced CCSM contraction after 
adding DPI, due to inhibition of NAD(P)H oxidase activity and ultimately OS. A 
similar finding has previously been reported (Puntmann et al, 2005). This inhibitory 
effect on OS is further strengthened by the observation that the addition of SOD also 
reduced the Ang II contractile response, albeit less profoundly than DPI. 
DPI-induced inhibition of the Ang II contractile response and OS also influenced 
NANC- and NO-mediated CCSM relaxation, since EFS and SNP-induced relaxations 
were significantly enhanced by this inhibitor. The fact that Ang II stimulates the ROS 
pathway through the induction of NAD(P)H oxidase is a clear indication of the 
importance of the Ang II/ROS pathway in penile pathophysiology. 
The findings reported here on; the interaction between Ang II and NO, inhibition of 
Ang II-induced CCSM contraction by losartan and the effect of OS on this process 
have important clinical significance/implications. Relaxation of corporal smooth 
muscle is a salient feature of the erectile process, as it allows the expansion of the 
lacunar spaces and reduces cavernosal venous outflow by compression of venules 
against the tunica albuginea, the surrounding fibrous structure (Azadozi et al,1992). 
Conversely, to maintain the penis in the flaccid state, the smooth muscle of penile 
arteries and trabeculae are kept contracted by the noradrenergic system, however 
other contractile mediators, such as Ang II also play an important role. This is 
supported by the finding that losartan had a significant protective role against 
structural changes in the vessels and cavernosal spaces of erectile tissue caused by 
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arterial hypertension, which was not the case for amlodipine, despite the fact that 
both drugs achieved systemic blood pressure control (Tobil  et al, 2004). 
Spontaneously hypertensive rats (SHR) treated with losartan alone or losartan 
combined with sildenafil for 6 months, was found to have functional and structural 
improvement to the erectile tissue when compared to non-treated animals (Tobil et 
al, 2007).  
Heme oxygenase (HO)-1 has been shown to be expressed in vascular smooth 
muscle cells (VSMCs), including those found in cavernous tissues (Abdel Aziz et al, 
2007). HO-1 gene expression exerts antioxidant actions, which participates in 
defense mechanisms against agent that induce oxidative injury (Abraham et al, 
2004). Ishizaka et al, (1997) stated that Ang II causes HO-1 gene down regulation in 
rat VSMCs, which might augment in vivo vasoconstriction, which was blocked by 
losartan. In addition, HO-1 gene expression, cGMP assay, HO enzymatic activity 
were significantly reduced in cavernous tissue from diabetic rats, due to diabetic OS 
but were significantly improved by losartan (Abdel Aziz et al, 2009). Taken together, 
these findings highlight the antioxidant action of losartan, reinforcing the concept that 
Ang II-induced OS is an integral part of its physiological action. 
3.5 Conclusion 
Ang II caused a dose dependent contraction of CCSM strips, an effect that was 
reversed by losartan the AT1 receptor antagonist. The interaction between Ang II 
and NO on CCSM function was also demonstrated. It is clear from the results that 
blocking NAD(P)H oxidase reduced OS and the contractile effect of Ang II, whilst 
enhancing NANC- and NO-mediated CCSM relaxation. Clearly, Ang II is a major 
contractile vasoactive peptide that contributes to the tonic contraction of CCSM and 
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blocking this pathway could be of significant importance in the understanding of the 
treatment of ED (see Chapter 5). 
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Chapter 4 
______________________________________ 
 
 
 
 
Effect of angiotensin II and its receptor 
antagonists on human corpus cavernosal 
contractility. 
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4.1. Introduction 
The important interactive role Ang II, its receptor antagonists, NO and OS play in 
modulating rabbit CCSM tone has been discussed in Chapter 3. However, this has 
not been confirmed using human CCSM tissue.  This confirmation is vitally 
important, since it has been reported that the penile contractile response to Ang II is 
species dependent (Klinge & Sjostrand, 1977). 
It is assumed that Ang II is involved in modulating the tone of human penile arteries 
and trabecular smooth muscle (Comiter et al, 1997; Becker et al, 2001) and that its 
regulation is governed by a balance with NO (Comiter et al.1997;Yan et al. 2003).  
Here, the effect Ang II and its receptor antagonists have on human corpus 
cavernosum contractility; together with their modulation of NO-mediated relaxation 
has been determined. The presence and distribution of Ang II in human corpus 
cavernosal tissue was also determined using immunohistochemistry. The results 
from this study provide an important insight in to the physiological role of Ang II 
during human penile erection. 
 
4.2. Materials and Methods 
4.2.1Tissue acquisition 
See Chapter 2 for details of tissue acquisition and experimental procedure. 
4.2.2 Effect of Ang II 
The effect of Ang II (10-8M – 10-5M) on CCSM function was investigated. As 
previously mentioned in the control rabbit experiments conducted in Chapter 3, 
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repeated applications of Ang II caused a marked desensitisation of the functional 
response leading to tachyphylaxis, making it difficult to construct a cumulative dose 
response curve, for this reason and to avoid tachyphylaxis a single dose of Ang II / 
individual human tissue was used in a dose range of 10-8M – 10-5M. 
 
4.2.3 Effect of Ang II receptor antagonists and L-NAME 
 The effect of Ang II on tissue strips was determined; the tissue was then washed 
over a 30 min period and exposed to either losartan (10-5 M; AT1 antagonist) or 
PD123,319 (10-5 M; AT2 antagonist) for 20 min before repeating the Ang II response. 
The effect of the vehicle (distilled water for 20 min) on the Ang II response was also 
determined. In other experiments L-NAME (10-4 M) was added to the bathing 
solution for 20 min and the effect on the Ang II (10-6 M) response determined. 
 
4. 2.4 Electrical field stimulation (NANC neurotransmission) 
 In a series of experiments, guanethidine (5 x 10-6 M), atropine (10-5 M) and 
indomethacin (10-6 M) were added to the bathing solution and left for 20 min to inhibit 
the adrenergic, cholinergic and cyclo-oxygenase pathways, respectively, leaving the 
NANC pathway intact. Tissues were then pre-contracted with phenylephrine (PE; 10-
4 M) followed by EFS of penile nerves with a Grass S88 (Astro-med Grass, Slough 
UK) stimulator. The stimulator delivered single square waves (duration 0.4 ms; 20V) 
at a frequency of 8.0 Hz in 5 s trains. In another experiment guanethidine was 
omitted from the cocktail of inhibitors, leaving atropine (10-5 M) and indomethacin 
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(10-6 M) in the bathing solution, which was left for 20 min. EFS measurements were 
again made at 8 Hz, followed by the addition of losartan and the EFS repeated. 
 
4.2.5 Electrical field stimulation (contractile response) 
 Guanethidine (5 x 10-6 M), atropine (10-5 M), indomethacin (10-6 M) and L-NAME 
(10-4 M) were added to the bathing solution and left for 20 min to inhibit the 
adrenergic, cholinergic, cyclo-oxygenase and NANC pathways, respectively. EFS 
measurements were performed with a Grass S88 stimulator, which delivered single 
square waves (duration 0.8 ms; 100V) at a frequency of 8.0 Hz for 5 s. Losartan was 
then added to the bathing solution for 20 min and the EFS measurements repeated. 
Tetrodotoxin was added at the end of each experiment to determine the component 
of the response that was due to direct muscle fibre stimulation. 
 
4.2.6  Effect of SNP 
 Tissue strips were pre-contracted with PE and cumulative response curves were 
constructed for SNP (3x10-7 - 10-6 M). The tissues were then washed several times 
followed by the addition of losartan to the organ bath for 20 min. The tissues were re-
contracted with PE and cumulative response curves were again constructed for 
SNP. 
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4.2.7 Effect of NAD(P)H oxidase inhibition on  Ang II and EFS-mediated   
responses 
The effect of apocynin, the NAD(P)H oxidase inhibitor (10-4M) on the Ang II (10-6M) 
response was determined. The effect of apocynin and losartan on EFS-mediated 
CCSM relaxation was also determined. 
  
4.2.8 Immunohistochemistry 
See Chapter 2 for the experimental procedure 
 
4.2.9 Statistical analysis 
The raw data from Ang II pre- and post- losartan and PD123,319 were expressed as 
% contraction of the PE contractile response. EFS and SNP tissue responses 
determined pre- and post-losartan were expressed as % relaxation of PE-induced 
tone. These were analysed and expressed as mean ± SEM using Graph Pad Prism 
4.0 software (see examples, Tables 5 & 6). Comparisons of the resultant Ang II dose 
response curves and SNP cumulative dose response curves were made using 
analysis of variance (2 way ANOVA, p < 0.05). Student’s unpaired and paired t-test 
statistical analysis was also determined on the raw data by the software package 
with statistical significance accepted at p < 0.05. The individual number of tissue 
strips used is included in the figure Legends. Strips from at least 5 animals were 
used in each experiment. 
 
 
 
 
 
 
 105 
4.3 Results 
4.3.1 Effect of Ang II on corpus cavernosal smooth muscle contraction 
 Ang II caused a dose dependent contraction (10-8M – 10-5M) of corpus cavernosal 
strips, which was significantly (ANOVA; P = 0.0006) reduced by losartan (Table 5, 
Figs 14 & 14a).   
In contrast, the addition of PD123319 had no significant effect on Ang II-mediated 
contraction (Fig 15). The addition of L-NAME significantly enhanced the Ang II-
induced contraction of corpus cavernosal strips by 32% (p=0.04). The addition of the 
vehicle (distilled water) did not significantly influence the Ang II response. 
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Table 5 : Ang II–induced contraction of corpus cavernosal strips pre- and post- losartan 
 
 
Strip No. Ang II 
10
-8
M 
% PE 
contraction 
Ang II 
10
-8
M post-los 
% PE 
contraction  
Ang II 
10
-7
M 
% PE 
contraction 
Ang II 
10
-7
M post-los 
% PE 
contraction  
Ang II 
10
-6
M 
% PE 
contraction 
Ang II 
10
-6
M post-los 
% PE 
contraction 
 
Ang II 
10
-5
M 
% PE 
contraction 
Ang II 
10
-5
M post-los 
% PE 
contraction 
1 29. 4.1 11.0 0.5 10.0 1.0 20.0 3.0 
2 37.0 4.0 23.0 7.0 36.0 1.0 6.0 1.0 
3 27.0 7.0 11.0 6.0 5.0 2.0 3.0 0.9 
4 60.0 44.0 7.0 1.3 13.0 1.0 2.0 0.5 
5 22.0 1.0 15.0 4.0 9.0 3.0 4.0 0.5 
6 2.8 0.8   8.0 1.0 1.6 7.0 
7     19.0 8.0 12.0 1.2 
8       3.0  
Mean 29.6 10.6 13.4 3.8 14.3 2.5 6.6 2.0 
Std. 
Deviation 
18.8 16.7 6.0 2.8 10.6 2.5 6.3 2.6 
Std. Error 7.7 6.8 2.7 1.3 4.0 0.9 2.2 0.9 
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Figure 14  
 
 
 
Figure 14: Representative tracing of Ang II (10-7 M)–induced contraction of a corpus 
cavernosal strip pre- and post- losartan. 
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Figure 14a 
 
 
 
 
 
Figure 14a. Ang II-induced contraction of human corpus cavernosal strips pre- (■) and post- 
(▲) losartan. *Denotes the data points where there was a significant difference in Ang II-
induced contraction pre- and post- losartan (Ang II (M): 10-8, p < 0.002; 10-7, p < 0.03;  
10-6, p < 0.009; 10-5, p < 0.006, paired Student’s t-test, n =5).  
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Figure 15:  
 
 
 
 
 
 
. 
 
 
 
 
 
 
Figure 15. Ang II-induced contraction of human corpus cavernosal strips pre- (■) and post- 
(▲) PD123,319 (n = 6). 
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4.3.2 EFS-induced cavernosal smooth muscle relaxation 
 EFS-induced relaxation of corpus cavernosal strips after exposure to guanethidine, 
atropine and indomethacin was increased by 29.4% following the addition of losartan 
(Fig 16).  
The losartan-induced increase in EFS relaxation of corpus cavernosal strips was 
greater (140%) when guanethidine was omitted from the cocktail of inhibitors (Fig 
17). 
Figure 16 
 
 
Figure 16. EFS-induced relaxation of human corpus cavernosal strips at 8 Hz following the 
addition of guanethidine, atropine and indomethacin, pre- and post-losartan. * Denotes a 
significant difference in EFS-induced relaxation pre- and post- losartan (p < 0.0009, n=9, 
paired Student’s t-test). 
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Figure 17 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. EFS- induced relaxation of human corpus cavernosal strips at 8 Hz following the 
omission of guanethidine from the cocktail of inhibitors, pre- and post-losartan. * Denotes a 
significant difference in EFS-induced relaxation pre- and post-    losartan (p = 0.027, n=7, 
paired Student’s t-test).  
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4.3.3 EFS-induced cavernosal smooth muscle contraction 
 EFS-induced contraction of corpus cavernosal strips following exposure to L-NAME, 
guanethidine, atropine and indomethacin was significantly reduced following the 
addition of losartan (p < 0.02, Fig 18).  
 
 
Figure 18 
 
 
 
 
 
 
Figure 18. EFS-induced contraction of human corpus cavernosal strips at 8 Hz following the 
addition of guanethidine, atropine, indomethacin and L- NAME, pre- and post-losartan. * 
Denotes a significant difference in EFS-induced contraction pre- and post-losartan (p < 0.02, 
n=7, paired Student’s t-test).  
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4.3.4 SNP-induced cavernosal smooth muscle relaxation 
 Cumulative response curves constructed for SNP showed that the relaxation of 
tissue strips was significantly enhanced by losartan (ANOVA; P<0.0001; Table 6, 
Figs 19 & 19a).  
 
 
Table 6: SNP-induced relaxation of corpus cavernosal strips pre- and post- losartan. 
Strip No. SNP       
10
-7 
M 
 
                
% PE 
relaxation 
SNP         
10
-7
 M     
post –los 
                     
% PE 
relaxation 
SNP 
3x10
-
 M 
 
               
% PE 
relaxation
 
SNP 
3x10
-7
 M 
post-los 
                        
% PE 
relaxation  
SNP     
10
-6
M 
 
             
% PE 
relaxation 
SNP    
10
-6
M 
post -los  
                 
% PE 
relaxation 
SNP      
3X10
-6
 M 
                          
                   
% PE 
relaxation 
SNP          
3X10
-6 
M  
post-los 
              
% PE      
relaxation 
1 19.0 49.0 31.0 49.0 49.0 51.0 50.0 53.0 
2 14.0 23.0 24.0 25.0 36.0 53.0 34.0 41.0 
3 13.0 15.0 4.0 13.5 19.0 40.0 57.0 82.0 
4 1.5 13.0 30.0 74.0 45.0 81.0 56.0 89.0 
5 14.0 16.0 30.0 75.0 45.0 89.0 56.0 93.0 
6 17.0 35.0 38.0 79.0 48.0 88.0 72.0 68 
7 24.0 70.0 39.0 41.0 37.0 37.0 73.0 77.0 
8 23.0 24.0 29.0 48.0 63.0 70.0 79.0 86.0 
9 24.0 35.0 47.0 48.0 70.0 71.0   
Mean 16.6 31.1 30.2 50.3 45.8 64.4 59.6 73.6 
Std. 
Deviation 
7.1 18.7 12.0 22.6 15.0 19.9 14.6 18.4 
Std. Error 2.4 6.2 4.0 7.5 5.0 6.6 5.2 6.5 
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Figure 19  
 
 
Figure 19: Representative tracing of SNP-induced relaxation of a corpus cavernosal strip 
pre- and post- losartan. 
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Figure 19a 
 
 
 
 
 
 
 
 
 
 
 
Figure 19a. SNP-induced relaxation of human corpus cavernosal strips pre- (●) and post- (■) 
losartan. * Denotes the data points where there was a significant difference in SNP-induced 
relaxation pre- and post-losartan (SNP (M): 10-7, p < 0.02; 3x10-7, p < 0.013; 10-6, p = 0.013; 
3x10-6, p < 0.04, paired Student’s t-test, n = 8).  
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4.3.5 NAD(P)H oxidase inhibition on Ang II  and EFS-mediated responses 
The NAD(P)H oxidase inhibitor apocynin significantly reduced the Ang II-induced 
contraction of corpus cavernosal strips, ( P = 0.006, Fig 20). Apocynin also 
potentiated EFS-induced relaxation when given with losartan by 33% (P=0.029). 
 
 
Figure 20 
          
 
 
 
 
 
 
 
Figure 20. Ang II-induced contraction (10-6 M) of human corpus cavernosal strips pre- and 
post-apocynin (10-4 M).*Denotes a significant difference in Ang II-induced contraction pre- 
and post-apocynin (P = 0.006, n=6, paired Student’s t-test).    
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4.3.6 Immunohistochemistry 
 Control sections showed no positive staining (Fig. 21a). Ang II was detected mainly 
in the endothelium of arterioles, with less immunoreactivity in smooth muscle 
bundles of the corpus cavernosum, and the endothelium lining sinusoids (Fig. 21b). 
CD34 immunostaining showed an extensive network of endothelium (Fig. 21c). 
Immunostaining for smooth muscle actin showed the bundles of smooth muscle in 
the corpus cavernosum (Fig. 21d).  
 
Figure 21 
 a   b   c   d  
     
 
 
 
Figure 21. Immunostaining of the corpus cavernosum on adjacent sections. (a) Negative 
control section. (b) Ang II is detected in the endothelium of arterioles (single arrow) and to a 
lesser extent in the endothelium of sinusoids (double arrow) and in smooth muscle bundles 
(arrowhead). (c) CD34 immunostaining shows a widespread network of endothelium. (d) 
Smooth muscle bundles are shown by smooth muscle actin immunostaining.  
 
 
 118 
4.4 Discussion 
This is the first study to comprehensively examine the effect of Ang II on human 
corpus cavernosal function and to outline the possible mechanism of action. Organ 
bath studies showed that Ang II caused a dose dependent contraction of cavernosal 
tissue through the activation of AT1 and not AT2 receptors. Although the penile 
contractile response to Ang II is species dependent (Klinge  et al,1977) the present 
finding supports previous studies using canine and rabbit cavernosal tissue (Comiter 
et al,1997;Park  et al 1997). It also supports work presented earlier in this Thesis 
(see Chapter 3).  
In addition, immunohistochemical studies revealed, for the first time, Ang II-
containing cells primarily distributed in human corpus cavernosal arteriolar 
endothelium, the interface between the sinusoidal cavities and to a lesser extent in 
smooth muscle. A similar distribution of Ang II immunohistochemical staining has 
also been reported in animal studies (Kifor et al, 1997). 
 As previously stated, the role of Ang II in the control of vascular tone and in the 
pathophysiology of CVD is well known (Oliver  et al, 1984; Cohn ,2006). The Large 
scope HOPE study demonstrated that the ACE inhibitor ramipril significantly reduced 
rates of cardiovascular death, myocardial infarction and stroke compared to placebo 
among patients with high risk of CVD (The heart out come prevention and evaluation 
study, 2000).The role of Ang II in other systems have also been demonstrated, for 
example, ACE inhibition is known to slow the progress of renal disease in patients 
with Type I DM (Lewis  et al ,1993). Several randomized controlled trails have also 
shown that Ang II receptor blockers slow renal disease progression in patients with 
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Type II DM and early or late stage renal dysfunction independent of blood pressure 
reduction (Lewis  et al, 1993; Karalliedde et al, 2006). 
 Here, using human tissue we confirm the findings of the rabbit study that Ang II, 
acting in a paracrine manner, is also a mediator of CCSM tone and contractility 
(Comiter et al,1997;Becker et al, 2001), providing a physiological role for this 
octapeptide in the human erectile process. This would also explain, at least in part, 
why Ang II is produced and secreted by the human corpus cavernosum in 
physiological amounts (Kifor et al,1997) and is higher in the cavernous blood during 
penile detumescence than in the tumescence phase (Becker et al, 2001). 
As previously mentioned, the deleterious effect Ang II has on penile erection is 
evident from in vivo experiments using anesthetised dogs where intracavernosal 
injections of the octapeptide terminated spontaneous erections. In contrast, the 
injection of losartan relaxed CCSM and caused penile erections by affecting tone 
and contractility of vascular smooth muscle within the blood vessels embedded in 
the corporal bodies, as well as the tone of the smooth muscles of the corpus 
cavernosum itself (Kifor  et al,1997). 
More recent work has shown that bilateral cavernosal nerve injury in a rat model 
caused a decrease in the erectile response, which was associated with up regulation 
of fibrotic activation in the penis, an effect that can be reversed with losartan, 
suggesting a role for Ang II in penile fibrosis following nerve injury. This may have 
clinical importance as this type of injury is common following pelvic surgery e.g. 
radical prostatectomy (Canguven  et al, 2009). 
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The Ang II-containing cells identified by immunohistochemistry presumably secrete 
their Ang II content on adrenergic stimulation, similar to vascular tissue (Kifor et al, 
1997). Our functional studies using losartan and PD123319 verify that the secreted 
Ang II acts on AT1 and not AT2 receptors to elicit the human corpus cavernosal 
contractile response, as reported in other species (Comiter et al, 1997;Becker et al, 
2001). 
The balance/functional interplay between Ang II and NO/cGMP have previously been 
reported in the vascular system (Sigmon et al, 1992; de Gasparo et al, 2002), as well 
as here using rabbit CCSM (Chapter 3). Several studies have suggested that NO 
might be a direct modulator of ACE activity (Higashi et al, 1995) and that Ang II may 
also have receptor-mediated effects on NOS activity and NO generation (Yan  et al, 
2003). Thus, an imbalance between these mediators is thought to be an important 
factor in the development of CVD (Yan C et al, 2003). Interestingly, impaired CCSM 
relaxation to ACh, diminished eNOS expression and increased VSMCs has been 
found in cavernous arteries taken from spontaneously hypertensive rats. All these 
parameters were improved by the combined treatment of losartan with sildenafil, 
implying that the enhancement of the NO/cyclic cGMP pathways by sildenafil 
supplements the actions of losartan by inhibiting the Ang II response through AT1 
receptor blockade ( Tobil et al, 2007). 
NANC neurotransmission is an important component of penile erection, since 
stimulating the cavernous nerve leads to smooth muscle relaxation (Burnett  et 
al,1997). Losartan significantly enhanced the EFS-induced relaxation of corpus 
cavernosal strips following the addition of guanethidine, atropine and indomethacin, 
inhibitors of the adrenergic, cholinergic and prostaglandin pathways, respectively. 
This finding is significant, since Ang II released via adrenergic stimulation should 
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have been blocked by guanethidine-induced chemical sympathectomy (Kempinas 
W,1998; Villanueva et al ,2003) making losartan ineffective. However, the data 
implies that guanethidine did not fully inhibit the adrenergic pathway. This is 
supported by previous studies; daily injections of guanethidine only destroyed 60-
70% of sympathetic nerves in adult rats (Robin et al ,2006), while guanethidine 
added to the bathing solution of rabbit thoracic aortic rings attenuated EFS-evoked 
noradrenaline release by 50% (Nap et al, 2001). Thus, EFS may be recruiting the 
remaining sympathetic neurones unaffected by guanethidine, causing the release of 
Ang II, which counteracts NANC neurotransmission. This would also explain why 
losartan had a significantly greater effect on EFS-induced relaxations when 
guanethidine was omitted from the bathing solution. 
The addition of L-NAME to the cocktail of inhibitors blocked the NO pathway 
resulting in EFS-induced contraction of corpus cavernosal strips. This contractile 
response is probably due to the recruiting of sympathetic neurones not affected by 
guanethidine causing Ang II-mediated contraction, which losartan reduced. As 
previously discussed, the release of NO from endothelial cells is also a vital step in 
the erectile process (Burnett  et al, 1997). Our group previously showed that NO and 
the NO donor SNP causes relaxation of CCSM tissue taken from control rabbits 
(Khan  et al ,2001a ;Thompson  et al ,2001). Here, we found that SNP caused a 
dose dependent relaxation of human corpus cavernosal strips, which was 
significantly enhanced following the addition of losartan. 
The interaction between Ang II and NO provides an insight into the possible 
mechanism of action of Ang II on corpus cavernosal contractility. As in the case of 
the rabbit experiments, the effect of Ang II is due to the physiological development of 
OS. In fact, in human blood vessels the membrane associated NAD(P)H oxidase is 
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thought to be the principle source of basal and Ang II-induced •O2
–, although other 
enzyme pathways are thought to play a role (West et al, 2001; Puntmann  et al, 
2005).   
We found the selective NAD(P)H oxidase inhibitor, apocynin reduced corpus 
cavernosal contraction and potentiated EFS-induced relaxation when given with 
losartan, both responses are probably due to the abolishment of •O2
–   generation, a 
similar conclusion was made in a study using vascular tissue (Lu et al, 2008). 
Further evidence of the role of OS in the action of Ang II is provided by the findings 
that showed the •O2
– scavenger superoxide dismutase significantly attenuated 
vascular smooth muscle contraction (Kawazoe et al, 2000). While pyrogallol a 
generator of •O2
– mimicked the Ang II enhancement (Lu et al, 2008). 
 
4.5 Conclusion 
Ang II-induced contraction of human CCSM plays a major role in the termination of 
penile erection; this has greater significance since the penis is usually in a flaccid/ 
detumescence state. The use of Ang II antagonists provides a vehicle to identify the 
underlying mechanistic interactions that involve the paracrine actions of Ang II.  For 
example, losartan potentiated SNP- and EFS-mediated CCSM relaxation, providing 
important evidence of the interplay between Ang II and NO/cGMP pathways in the 
regulation of human corpus cavernosal tone. Evidence presented in this Thesis also 
supports the concept that OS plays a significant role in Ang II –induced contraction 
of corpus cavernosal tissue an effect mediated by the production of •O2
–.  It is, 
therefore, conceivable that a disruption in the delicate interaction between these 
mediators may play a significant role in the development of ED. 
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Chapter 5 
______________________________________ 
 
 
 
 
 
 
The effect of angiotensin II on corpus 
cavernosal function from partial bladder outlet 
obstructed rabbits. 
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5.1 Introduction 
 It is now recognised that benign prostatic hyperplasia (BPH) can cause partial 
bladder outlet obstruction (PBOO) (Berry et al, 1984), resulting in structural and 
functional changes to the bladder that can influence the storage and emptying of 
urine, with many patients developing detrusor overactivity (Eckhardt et al, 2001). The 
clinical consequences of PBOO associated with BPH (Mauroy, 2008), including 
urodynamics and structural changes in bladder pathophysiology can be reproduced 
in animal models, by tying a ligature around the proximal urethra at the base of the 
bladder neck (Beamon et al, 2008; Calvert et al, 2001a). An increase in bladder 
mass, as well as hypertrophy and hyperplasia of bladder smooth muscle, with 
thickening of the outer serosal layer have been reported in rabbits following this 
procedure (Calvert et al, 2001a). Functional studies have also revealed a reduction 
in electrical field stimulation (EFS) and chemical-induced bladder smooth muscle 
contraction (Lin et al, 2007), supporting the clinical findings of impaired bladder 
function following PBOO.   
There has been a continuing debate as to whether there is a link between BPH and 
ED. Although some clinical studies suggest an association, (Namasivayam et 
al,1998; Rosen et al, 2009), where sexual performance is related to the severity of 
BPH (Baniel et al, 2000), a literature based study could not identify this link (Vale, 
2000). However, the use of the PBOO animal model has helped to investigate this 
association (Chang et al, 2000; Lin et al, 2008). Our group were the first to show 
increased collagen deposition in the corpus cavernosum (Khan et al, 1999) and 
preliminary evidence of impaired corpus cavernosal smooth muscle (CCSM) 
relaxation in a chronic PBOO rabbit model (Calvert et al, 2001b and c). This has 
been substantiated by the findings that endothelium-dependent (ACh-mediated) and 
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endothelium-independent (ATP/SNP-mediated) CCSM relaxation is impaired, with a 
marked reduction in smooth muscle cells in this model (Lin et al, 2008). These 
findings imply that PBOO animals exhibit many of the features of ED and offer a test 
bed to determine its influence on other components of the erectile process, for 
example pro-contractile mechanisms, which terminate penile erection by keeping the 
smooth muscle of the penile arteries and trabeculae contracted (Holmquist et al, 
1992).This is of particular importance, since unlike most smooth muscle cells those 
of the corpus cavernosum spend the majority of the time contracted (Chang et al, 
2002). 
Ang II as previously determined is an important mediator of human CCSM 
contractility and tone and that its regulation is governed by a balance with NO 
(Chapter 4).  
Here, we determined the effect Ang II, AT1 receptor inhibition and OS have on 
CCSM contractility, together with their modulation of NO-mediated relaxation in a 
chronic rabbit model of PBOO. The results from this study provide important 
information on the pathological role of Ang II in ED.  
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5.2 Materials and Methods 
5.2.1 Induction of partial bladder outlet obstruction (PBOO) and tissue 
aquisition 
See Chapter 2 for details of experimental procedure and tissue acquisition. 
 
5.2.3 Organ bath studies 
The tissue strips were mounted vertically in 10 ml organ baths, equipped with two 
parallel platinum electrodes for EFS (See Chapter 2 & 3 for details). Tension was 
applied to the suspended tissue strips and left for 1h to equilibrate (tension recorded 
on a Grass Polygraph, model 7D; Astro-med Grass, Slough, UK).  
 
5.2.4 Effects 
5.2.4.1 Bladder weights:  
The bladders were excised from sham-operated and PBOO rabbits after 8 weeks 
and weighed.  
 
5.2.4.2 Ang II  
The effect of Ang II (10-8M – 10-5M) on CCSM function was investigated using tissue 
strips from sham-operated and PBOO rabbits.  
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5.2.4.3 Ang II receptor antagonists 
After the effect of Ang II on tissue strips taken from sham-operated and PBOO 
rabbits were determined; the tissues were washed over a 30 min period and 
exposed to losartan (10-5 M) for 20 min before repeating the Ang II response. The 
effect of the vehicle (distilled water for 20 min) on the Ang II response was also 
determined.  
 
5.2.4.4 Oxidative Stress  
5.2.4.4.1 DPI  
The effect diphenylene iodonium chloride made up in DMSO (DPI, 10-4M, NAD(P)H 
oxidase inhibitor, which inhibits •O2
–  production)  has on the Ang II (10-6M) response 
from sham-operated and PBOO tissue strips was determined. 
3.2.4.4.2 SOD 
The effect superoxide dismutase (SOD, 200 IU/ml; the enzyme that accelerates the 
breakdown of •O2
–) has on the Ang II (10-6M) response from sham-operated and 
PBOO tissue strips was also determined. 
 
5.2.4.5 Electrical Field Stimulation 
NANC neurotransmission 
 In a series of experiments CCSM tissue from sham-operated and PBOO animals 
were exposed to guanethidine (5 x 10-6 M), atropine (10-5 M) and indomethacin (10-6 
M), which were added to the bathing solution and left for 20 min to inhibit the 
adrenergic, cholinergic and cyclo-oxygenase pathways, respectively, leaving the 
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NANC pathway intact. The tissue strips were then pre-contracted with PE followed 
by EFS of penile nerves with a Grass S88 (Astro-med Grass, Slough, UK) stimulator. 
The stimulator delivered single square waves (duration 0.4 ms; 100V) at a frequency 
of 8.0 Hz in 5 s trains. Losartan and DPI was then added and the EFS repeated. 
 We choose 8 Hz since this stimulation frequency is ideal to evaluate the effect of 
losartan on NANC neurotransmission (Chapter 3 & 4). 
 
5.2.4.6 SNP 
CCSM tissue strips from sham-operated and PBOO rabbits were pre-contracted with 
PE (10-4M) and cumulative response curves were constructed for the NO donor 
SNP, 10-7 – 3x10-6 M). 
 
5.2.4.7 Losartan  
In another series of experiments SNP cumulative response curves were again 
constructed using CCSM tissue from PBOO animals. The tissue was washed several 
times before the addition of losartan (10-5 M) to the organ bath for 20 min and re-
contracted with PE and a cumulative response curve constructed for SNP. 
 
 3.2.5 Statistical Method 
The raw data from Ang II tissue responses were expressed as mg tension / mg 
tissue. EFS and SNP tissue responses were expressed as % relaxation of PE-
induced tone. These were analysed and expressed as mean ± SEM using Graph 
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Pad Prism 4.0 software (see examples, Tables 7 & 8). Comparisons of the resultant 
Ang II dose response curves and SNP cumulative dose response curves were made 
using analysis of variance (2 way ANOVA, p < 0.05). Student’s unpaired and paired 
t-test statistical analysis was also determined on the raw data by the software 
package with statistical significance accepted at p < 0.05.  The individual number of 
tissue strips used is included in the figure Legends. Strips from at least 5 animals 
were used in each experiment. 
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5.3 Results 
3.3.1 Bladder weight 
There was a significant increase in rabbit bladder weights following 8 weeks PBOO 
when compared with sham-operated animals (sham-operated rabbits, median 2.0g, 
range 1.7 - 2.8g  vs  PBOO rabbits, median 20.0g, range10 - 42.0g; n =13 p<0.0001 
unpaired Mann Whitney, Figure 22). 
 
 
 
 
 
 
 
 
Figure 22. Representative urinary bladder from a PBOO rabbit (42g, left) and a sham-
operated rabbit (2g, right) 8 weeks after surgery. 
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5.3.2 Ang II and CCSM contraction 
 The size and weight of cavernosal strips from sham-operated and PBOO rabbits 
were similar. Ang II caused a dose dependent contraction (10-8M – 10-5M) of CCSM 
strips from sham-operated and PBOO rabbits, which was markedly increased in the 
PBOO group and reduced by losartan (Fig 23). The addition of the vehicle did not 
significantly influence the Ang II response in any experiment.  
 
 
 
Figure 23 
 
 
 
 
 
 
 
 
Figure 23. Ang II-induced contraction of CCSM strips taken from PBOO rabbits (■) was 
significantly (P<0.01) increased compared with sham-operated animals (▲). The PBOO-
induced increase in CCSM contractility was significantly reduced post-losartan (▼), P 
<0.0001, n = at least 5 strips/concentration.  
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5.3.3 Oxidative Stress 
5.3.3.1 CCSM contraction. DPI and SOD reduced the Ang II-induced contraction of 
CCSM strips from sham-operated and PBOO rabbits. (Table 7,Figs 24, 24a &24b ).  
 
Table 7: Ang II–induced contraction of corpus cavernosal strips pre- and post- SOD 
 
 
Strip No. Ang II  10-
5M 
 
%PE 
Contraction 
Ang II 
 10-5M 
post-SOD 
%PE 
Contraction 
1 68.0 57.0 
2 56.0 33.0 
3 46.0 35.0 
4 74.0 55.0 
5 73.0 63.0 
6 51.0 51.0 
7 43.0 39.0 
8 29.6 10.6 
Mean 58.7 47.6 
Std. 
Deviation 
12.9 11.8 
Std. Error 4.9 4.4 
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Figure 24 
 
 
 
 
 
 
Figure 24: Representative tracing of Ang II (10-6 M)–induced contraction of a corpus 
cavernosal strip pre- and post- DPI. 
 
 
PE 
Ang 10-6 Ang 10-6 DPI 
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Figure 24a 
 
 
 
 
 
 
 
Figure 24a: Representative tracing of Ang II (10-6 M)–induced contraction of a corpus 
cavernosal strip pre- and post- SOD. 
 
PE Ang 10-6 Ang 10-6 SOD 
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Figure 24b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24b. Ang II-induced contraction (10-6 M) of corpus cavernosal strips taken from 
sham-operated and PBOO rabbits was significantly decreased post-DPI (10-4 M), * p<0.03, 
** p=0.001 and not significant post-SOD (200UI/ml), n = at least 5 strips, unpaired Student’s 
t-test.   
 
 
 
A
n
g
 I
I 
s
h
a
m
A
n
g
 I
I 
s
h
a
m
 p
o
s
t-
D
P
I
A
n
g
 I
I 
s
h
a
m
 p
o
s
t-
S
O
D
A
n
g
 I
I 
P
B
O
O
A
n
g
 I
I 
P
B
O
O
 p
o
s
t-
D
P
I
A
n
g
 I
I 
P
B
O
O
 p
o
s
t-
S
O
D
0
10
20
30
40
50
60
70
*
**
M
a
x
im
a
l 
c
o
n
tr
a
c
ti
o
n
m
g
 t
e
n
s
io
n
/m
g
 t
is
s
u
e
 
 
 136 
5.3.3.2 CCSM relaxation 
 EFS-induced CCSM relaxation of sham-operated and PBOO strips, was increased 
following adrenergic, cholinergic and cyclo-oxygenase inhibition and in the presence 
of losartan (Fig 25). In addition, EFS-induced CCSM relaxation of PBOO strips was 
increased by 18.4% following addition of the triple inhibitors (guanethidine, atropine 
and indomethacin), and in the presence of DPI.  
 
Figure 25 
 
 
Figure 25. EFS-induced relaxation of corpus cavernosal strips taken from sham-operated 
and PBOO rabbits at 8 Hz (following the addition of guanethidine, atropine and 
indomethacin) was significantly increased post-losartan * p<0.02, n = at least 5 strips, paired 
Student’s t-test.    
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3.3.4 SNP and CCSM relaxation 
SNP-induced relaxation of CCSM strips taken from PBOO rabbits was impaired 
when compared with sham-operated animals and improved by losartan (Table 8, 
Figs 26, 26a ). 
 
Table 8 : SNP-induced relaxation of corpus cavernosal strips pre- and post- losartan. 
 
 
Strip No. SNP 10
-7 
M 
 
% PE 
relaxation 
SNP 10
-7
M 
 post –los 
% PE 
relaxation 
SNP 3x10
-7
M 
 
% PE 
relaxation
 
SNP 3x10
-7
 M 
post-los 
% PE 
relaxation  
SNP 10
-6
M 
 
% PE 
relaxation 
SNP 10
-6
M 
post -los  
% PE 
relaxation 
SNP3X10
-6
 M 
 
% PE 
relaxation 
SNP 3x10
-6
 M 
post-los 
% PE 
relaxation 
1 15.0 22.0 26.0 36.0 38.0 68.0 50.0 80.0 
2 14.0 10.0 17.0 16.0 29.0 37.0 54.0 63.0 
3 2.0 2.4 7.0 7.0 28.0 45.0 48.0 52.0 
4 4.0 4.0 5.0 8.0 32.0 35.0 46.0 60.0 
5 5.0 9.0 21.0 35.0 45.0 47.0 47.0 67.0 
6     29.0 30.0   
7     32.0 35.0   
Mean 8.0 9.5 15.3 20.4 33.3 42.4 49.0 64.4 
Std. 
Deviatio
n 
6.0 7.7 8.8 14.2 6.2 12.8 3.1 10.3 
Std. 
Error 
2.7 3.4 3.9 6.4 2.3 4.8 1.4 4.6 
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Figure 26 
 
 
 
 
Figure 26: Representative tracing of SNP-induced relaxation of a corpus cavernosal strip 
pre- and post- losartan. 
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Figure  26a 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. SNP-induced relaxation of CCSM strips taken from PBOO (■) rabbits was 
significantly (P <0.0001) impaired compared with sham-operated (▼) animals and was 
significantly improved post-losartan (▲), P<0.01, n = at least 5 strips.  
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5.4 Discussion 
This study shows, for the first time, a dose dependent enhancement of the Ang II-
induced contraction of CCSM tissue taken from PBOO rabbits when compared with 
sham-operated controls. It also supports previous findings using human and normal 
rabbit corpus CCSM tissue, which revealed the Ang II–mediated contractile response 
is due to AT1 receptor activation with the development of OS (Chapter 3 & 4) 
The present findings demonstrate that Ang II increases CCSM contraction as a 
pathological consequence of PBOO. We have used only one concentration of Ang II 
on each individual tissue strip, since multiple application of Ang II to isolated human 
arteries results in a marked desensitisation of the functional response (i.e. 
tachyphylaxis) (Hidaka et al, 2005).  This phenomenon may explain the large 
variation in the Ang II 10-5M error bar following PBOO (Fig 23).  
Results from previous studies using PE as a mediator of CCSM contractility following 
PBOO in rabbits are inconclusive. Chang et al, 2002. noted a 50% increase in CCSM 
contractile force after 2 weeks PBOO, due to an increase in smooth muscle bundles 
and cellular alterations in the contractile myosin-isoform composition. This increased 
contractility was not evident in the studies of Demir et al, 2008. and Lin et al, 2008. at 
a similar time point. This is possibly due to post-operative inflammation in the sham-
operated group and a reduction in CCSM cells, respectively. Results from chronic 
PBOO studies have revealed a time-dependent change in the contractile response. 
Demir et al., found an increase in CCSM contractility after 4 weeks PBOO, as the 
inflammatory response in the sham-operated group subsided. Whereas, Lin et al., 
found the contractile response was reduced at 8 weeks, due to a reduction in CCSM 
content and an increase in collagen deposition.  
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 In an attempt to shed more light on the changes in corpus cavernosal function 
following chronic PBOO, we conducted our experiments using Ang II a known 
physiological mediator of human and rabbit CCSM contraction. Our data suggest 
that the contractile capacity of each individual smooth muscle cell is increased in this 
model, even though the overall numbers are reduced due to collagen deposition (Lin 
et al, 2008) a finding that may have clinical relevance in the development of ED. This 
is in keeping with a previous study that showed PE elicited an increased contractile 
response of CCSM strips taken from men with ED, suggesting an increase in 
corporal vascular smooth muscle contractility may contribute to the pathophysiology 
of ED in older men (Christ et al, 1991). 
 The PBOO-induced augmentation of the Ang II pathway could be due to an increase 
in Ang II release and/or AT1 receptor density, increased coupling efficiency of the 
agonist-receptor complex to the signal transduction machinery and/or increased 
amplification of second messenger formation subsequent to receptor activation. 
While the importance of each potential mechanism is uncertain, it is likely an 
increase in OS and excessive •O2
– production is involved. The role of OS in the Ang 
II-mediated contraction of human corpus cavernosum is known (Chapter 4). We 
found the selective NAD(P)H oxidase inhibitor DPI significantly attenuated Ang II-
induced CCSM contraction in sham-operated and PBOO rabbits. Although, the 
reduction in the Ang II response induced by the •O2
–   scavenger SOD was not 
significant, this trend particularly following PBOO suggests that SOD, similar to DPI 
is capable of reducing OS. The effectiveness of these drugs is probably due to the 
abolishment of •O2
–   generation. Similar observations have been reported using 
vascular tissue (Kawazoe et al, 2000; Lu et al, 2008), while pyrogallol a generator of 
•O2
– mimicked the Ang II enhancement (Lu et al, 2008).  
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NANC neurotransmission is an important component of penile erection, since 
stimulating the cavernous nerve leads to smooth muscle relaxation (Burnett et al, 
1997). This pathway is impaired following PBOO (Lin et al, 2008), providing further 
evidence of the development of ED in this model. Losartan significantly increased 
the EFS-induced relaxation of corpus cavernosal strips taken from PBOO rabbits 
following cholinergic, prostaglandin and adrenergic inhibition. However, as Ang II 
release is via adrenergic stimulation, guanethidine should have blocked this pathway 
making losartan ineffective. The data implies that guanethidine does not fully inhibit 
the adrenergic pathway during EFS-induced relaxation, a point previously discussed 
in Chapter 4. 
Our findings also confirm that SNP-mediated relaxation of CCSM tissue is impaired 
in chronic PBOO rabbits as previously reported (Calvet et al, 2001b; Lin et al, 2008).  
This reinforces the concept that this model demonstrates the salient features of ED.  
Losartan significantly improved the SNP-mediated relaxation of CCSM strips taken 
from PBOO rabbits, highlighting the interplay between Ang II and NO/cGMP, 
implying that an imbalance between these mediators is an important factor in the 
development of ED. Interestingly, an inverse correlation between Ang II 
responsiveness and endothelium-dependent relaxation has been demonstrated in 
isolated human arteries, which was related to the development of OS (Voors et al, 
2005). 
The actions of losartan may have clinical importance in ED management. For, 
although PDE 5 inhibitors have become extremely effective oral agents for the 
treatment of ED, it has become increasingly apparent not all patients respond to this 
form of therapy (Shabsigh et al, 2000), moreover, some who initially respond 
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develop tachyphylaxis or discontinue their use due to loss of efficacy (El-Galley et al, 
2001), Thus, the use of an Ang II antagonist, which reduce CCSM contractility, in 
conjunction with a PDE5 inhibitor that increases CCSM relaxation, may be beneficial 
for ED patients; not only by reducing the percentage of none responders but also the 
concentration of PDE 5 inhibitor required to maintain erection. This could explain, at 
least in part, why long-term losartan and PDE5 combination therapy has a beneficial 
effect on the structure and function of CCSM tissue taken from SHR (Toblli et al, 
2007). 
5.5 Conclusion 
Ang II causes a pathological enhancement of CCSM contraction from PBOO rabbits 
that was inhibited by losartan, probably due to a direct/indirect reduction in •O2
– 
production and OS. Losartan improved the impaired SNP/EFS-mediated relaxation, 
providing important evidence of the interplay between Ang II and NO/cGMP 
pathways in the regulation of CCSM tone. Elevated Ang II responsiveness, together 
with impaired relaxation of CCSM, may play a pivotal role in the development of ED. 
Further studies are required to determine the molecular events responsible for the 
cellular changes to CCSM in PBOO. 
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Chapter 6 
________________________________________ 
 
 
 
 
 
 
GENERAL DISCUSSION  
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6.1 Correlation between PBOO and structural/functional changes to 
the corpus cavernosum. 
Although PBOO is associated with direct changes to the CCSM, the mechanism(s) 
responsible for these changes are unclear. It seems unlikely that it is due to direct 
injury/trauma during surgery, since these changes were not evident in the sham-
operated rabbits. It is, however, possible that constant compression of the nerves 
that travel through the bladder neck region and supply the corpus cavernosum 
caused by the partial ligation of the urethra, could have lead to a decrease in 
cavernosal innervation. This idea is supported by immunohistochemical staining of 
corpus cavernosal tissue taken from PBOO rabbits, which revealed decreased 
neuronal innervation (Chang et al, 2002).   
Another explanation can be derived from the increased bladder mass and bladder 
overdistention associated with PBOO. In this scenario, stretching the nerves of the 
pelvic plexus or compressing small arteries in the base of the bladder would lead to 
ischemia of the corpus cavernosum, which in turn, could affect corpus cavernosal 
function (Chang et al, 2002).    
  
6.2 Corpus cavernosal tone: balance between relaxing and 
contractile pathways.  
Penile erection ultimately depends on the relationship between contractile and 
relaxation mechanisms acting on the smooth muscle cells of the corpus cavernosal 
arterioles and sinuses. CCSM relaxation and inhibition of contraction permits 
increased arteriolar blood inflow that fills and expands the corpus cavernosal 
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sinuses. This occurs in conjunction with a concomitant reduction in the rate of 
venous blood outflow due to veno-occlusion. 
The balance/interplay between contracting and relaxant factors is paramount, since 
this phenomenon controls penile vasculature tone. The importance of NO in the 
erectile process is irrefutable, since it stimulates the intracellular production of 
NO/cGMP (Burnett, 1997), from both NANC nerves (Lue, 2000; Maggi et al, 2000) 
and the corpus cavernosal endothelial cells (Hedlund  et al, 1985). This initiates 
CCSM relaxation and ultimately penile erection (Trigo-Rocha et al, 1993).  
Importantly, it must be remembered that the penis remains in the flaccid state most 
of the time, thus, maintaining physiological CCSM basal tone. Although, the 
understanding of the various vasoconstrictor agents responsible for this functional 
phase remains incomplete, endothelin-1, serotonin, as well as adrenergic agonist 
have all been implicated/ investigated in this regard (Saenz De Tejada et al, 1991; 
Lau et al, 2006; Wingard et al, 2001). The role of Ang II is of particular interest, since 
it is produced by human CC tissue, as demonstrated in the immunohistochemical 
study and secreted in physiological amounts (Kifor et al, 1997), acting in a paracrine 
manner when causing CCSM contraction. This supposition is supported by the 
finding that the cavernosal blood level of Ang II is higher during flaccidity than when 
the penis is erect (Becker et al, 2001).    
Both the rabbit and human studies presented in this Thesis (Chapter 3 & 4) using 
CCSM tissue from control animals and gender reassignment patients, respectively, 
highlight the important role Ang II plays in maintaining “normal” CCSM tone. A 
feature of these studies was the decision not to follow previous experimental 
protocols when determining the effect of Ang II on CCSM function. Other studies 
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have attempted to produce a cumulative dose response curve for Ang II-induced 
CCSM contraction. However, here it was recognised that such an approach might 
lead to erroneous results/invalid interpretation of the data. This is because multiple 
application of Ang II to isolated CCSM tissue results in a marked desensitisation of 
the functional response (i.e. tachyphylaxis). This is consistent with the findings from 
a previous study using isolated human arteries (Hidaka et al, 2005). Thus, to avoid 
this problem, only one concentration of Ang II was used on each individual tissue 
strip.  
 
6.3 Ang II and NO interaction in CCSM 
Previous work on the cardiovascular system has revealed the functional interaction 
between NO and Ang II (de Gasparo, 2002). Thus, NO antagonises the 
vasoconstrictor and pro-atherosclerotic effect of Ang II, whereas Ang II decreases 
the bioavailability of NO through OS (Chen et al, 2007). However, until now, little 
work has been carried out using CCSM tissue. In fact, the only study which 
demonstrated the interaction between Ang II and NO was carried out on canine 
CCSM tissue, which showed that modulation of Ang II could be achieved by 
changing the local NO environment (Comiter et al, 1997). However, that study did 
not mention the important role OS played in this interaction. With the use of a 
specific inhibitor of •O2
– production and the enzyme that accelerates the breakdown 
of •O2
–, the precise involvement of OS has been determined in this Thesis. This 
information is particularly important for a clearer understanding of human penile 
physiology, since the effect of Ang II on CCSM function is species-dependent. The 
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data presented here using rabbit and human CCSM tissue confirms that the erectile 
process is similar in both species.  
The finding that losartan the AT1 receptor antagonist blocked rabbit and human 
CCSM Ang II-induced contraction and potentiated EFS- and SNP-induce relaxation 
of CCSM strips, while L-NAME potentiated the Ang II induce contraction, as well as 
the EFS-induced contraction adds further credence to the notion of NO/Ang II 
interaction.  
Based on these findings it is reasonable to assume that an imbalance between these 
mediators could be involved, at least in part, in the development of ED. 
 
6.4 The role of Ang II and oxidative stress on CCSM function. 
It is well described that Ang II increase the production of •O2
– through the activation 
of NAD(P)H oxidase (Lassegue et al, 2003) and the ROS produced by Ang II 
contributes to the pathogenesis of CVD by reducing NO, impairing endothelial 
function, and stimulating proatherogenesis (Cathcart,  2004). 
Clearly, the finding that apocynin and DPI, the selective NAD(P)H oxidase inhibitors 
reduce human and rabbit  CCSM contraction, reflects the involvement of OS due to 
the abolishment of •O2
–   generation. Inhibiting OS also had an impact on NANC 
neurotransmission. EFS-induced relaxation was further improved by adding 
apocynin and losartan, when compared with losartan alone, suggesting that blocking 
the AT1 receptor alone does not fully inhibit OS.  This is the first study to provide 
compelling experimental evidence that the development of OS is instrumental in 
human erectile physiology. 
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6.5 The role of Ang II/NO and oxidative stress in PBOO: a model of 
ED 
A recent survey of patients above 50 years old demonstrated a strong link between 
ED and the severity of LUTS (Song et al, 2011). Experimental studied using animal 
models with PBOO have also demonstrated CCSM structural and functional changes 
in line with the development of ED. For example, CCSM tissue obtained from rabbits 
with PBOO showed increased deposition of collagen with a reduction in the density 
of smooth muscle cell/fibres (Khan et al, 1999, Lin et al, 2008). This was 
accompanied with impaired CCSM relaxation to SNP and EFS; a feature of ED. In 
the present study this model has been used to determine CCSM functional changes 
induced by Ang II and its relationship with NO and OS. It was found, for the first time, 
that Ang II caused a marked and significant increase in CCSM contraction in PBOO. 
The importance of this observation is even greater when it is considered in the 
context of a reduction in CCSM cells and impaired EFS- and SNP-mediated 
relaxation. The findings with   Ang II imply that PBOO increases OS. This is 
supported by the DPI- and SOD-induced reduction in the Ang II-mediated CCSM 
contraction. Two further observations using this model may have profound clinical 
significance in the treatment of ED. Losartan significantly reduced the Ang II 
response and improved SNP-mediated CCSM relaxation. These findings further 
strengthen the concept of interplay between Ang II and NO/cGMP and that an 
imbalance between these mediators maybe a factor in the development of ED. In 
terms of ED management the use of a PDE 5 inhibitor in conjunction with an Ang II 
antagonist could have clinical benefit.  
 
 
 150 
However, it is essential that these findings are confirmed using other experimental 
models, for example, DM rabbits. DM-induced impairment of CCSM relaxation is 
known to have a deleterious effect on penile erection, which explains why the 
incidence of ED is as high as 70% in diabetic men (Lerner, et al 1993; Ziegler, et al 
2006) and why these patients are some times referred to as a “difficult-to-treat” ED 
group (Ishii, et al 2006). The use of the diabetic rabbit model is ideal, since these 
animals exhibit many features of human DM, including ED. Previously studies using 
diabetic rabbits have shown that impaired CCSM relaxation is improved by PDE 5 
inhibition (Thompson et al, 2001; Lau et al 2009). It would be interesting to see if 
losartan-induced inhibition of Ang II resulted in a complimentary improvement in 
CCSM function. Other studies have highlighted the beneficial effect of losartan on 
the erectile process. The antioxidant quality of losartan was found to directly inhibit 
OS in diabetic rats (Abdel Aziz et al, 2009). It is also known to preserve the erectile 
function after bilateral cavernosal nerve injury in rats, by opposing the development 
fibrosis (Canguven et al, 2009). While, a clinical study that compared patients with 
hypertension alone against those with hypertension and ED found that losartan 
significant improved sexual satisfaction in the ED group (Llisterri et al, 2001).  
 
6.6 Conclusion 
In this thesis I have determined the role, at least in part; Ang II plays in corpus 
cavernosal erectile pathophysiology. To achieve this I have used CCSM tissues from 
three experimental models; control rabbits, gender reassignment men, as well as 
PBOO rabbits. The findings clearly demonstrate that Ang II works in a paracrine 
manner, since it is produced by and acts on the corpus cavernosum.  
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Using immunohistochemistry I have identified the presence of Ang II in the 
endothelium of human corpus cavernosum and blood vessels, as well as in the 
smooth muscle tissue. In addition, Ang II caused a dose-dependent contraction of 
CCSM in all three models, a response that was blocked by the AT1 receptor 
antagonist losartan but not by AT2 receptor inhibition.  
I have also examined the interaction between Ang II and NO using NO donors and 
inhibitors of both vasoactive mediators, together with their effect on NANC 
neurotransmission. Evidence is provided that Ang II modulates NO-mediated CCSM 
relaxation, a response that is paramount in controlling CCSM tone. I have further 
expanded the work by looking at the role of OS on Ang II-induced CCSM contraction. 
Results indicate that inhibitors of OS significantly diminish the contractile effect of 
Ang II and improve the relaxation of the CCSM tissue.  
In summary, I have found for the first time, Ang II-mediated CCSM contraction is 
enhanced in a rabbit PBOO model, (known to have impaired CCSM relaxation) and 
inhibited by losartan. These observations have clinical significance, since it implies 
the use of an AT1 receptor antagonist, in conjunction with a PDE5 inhibitor may 
provide a novel treatment option for ED. 
6.7 Limitation of the study  
During the course of this study I came across a few obstacles, which limited the 
scope of the work. The first relates to the inability to reproduce previous work, 
namely developing cumulative dose response curves for Ang II, in the presence and 
absence of its antagonist. I found the contractile effect of Ang II on CCSM strips was 
short lived with the peak response not sustained long enough to achieve a plateau. 
This resulted in an undulating curve that was not only difficult to interpret, but 
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potentially gave misleading results. In order to avoid this, I used a single Ang II dose 
on each tissue strip; this meant data generation was very slow and limited the 
amount of experiments I could do, making the study more expensive.  
Developing the PBOO rabbit model was another challenging task, although this 
model has been previously described, the possibility of post-operative complication 
was a major concern, as unlike humans rabbit are highly likely to develop fibrosis 
and adhesions. One way to avoid this was to use liberal and constant saline 
irrigation during the surgical procedure and when closing the wound. Although, this 
approach was successful, it did not totally eliminate the problem; as a few animals 
did develop adhesions and were terminated before the end of the study. 
Including a diabetic rabbit model in this study would have added valuable data, as 
this is a known model of ED and increased OS. Unfortunately, due to time 
constraints and the expensive of establishing and maintaining this model, it was not 
included.  
6.8 Future work 
There are several areas of study, which should be pursued as a result of the findings 
I have presented in this thesis. This work could provide further insight into the effect 
of Ang II on the pathophysiology of ED. 
1. To confirm the Ang II findings using another model of experimental ED, such 
as the diabetic rabbit model. 
2. To determine if the enhanced Ang II-mediated contraction of CCSM tissue 
taken from PBBO rabbits is reversible. This could be assessed by removing 
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the ligature around the base of the bladder at timed intervals after establishing 
PBOO, before carrying out the Ang II experiments. 
3. The clinical relevance of the findings could be determined by repeating the 
experiments using cavernosal biopsies from men with PBOO and diabetes.  
4. The work presented in this thesis was mainly a functional study, with some 
immunohistochemical data revealing the distribution of Ang II in the corpus 
cavernosum. More work is required to determine the cellular/molecular 
mechanisms that govern the Ang II response on the corpus cavernosum. This 
could be achieved by isolating CCSM cells from PBOO/ diabetic rabbits and 
determine the effect Ang II and its antagonist have on the cellular contractile 
apparatus using confocal microscopy, chemiluminescence and Western Blott 
analysis.  
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